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Menopause causes declines in ovarian hormones such as estrogens and progesterone. 
During the menopausal transition, women may experience adverse symptoms such as 
anxiety, depression and lack of desire to interact. However, since the publication of the 
Women’s Health Initiative (WHI) many women have been left asking questions about 
whether, when, and how long to take hormone treatments for menopausal symptoms. 
This dissertation focuses on the effects of timing and duration of estradiol (E2) relative to 
loss of ovarian hormones (OVX) on the social brain and behavior in mature adult (MAT) 
and aging (AG) female rats. The results from these studies illustrated that in MAT rats, 3-
months of E2 given immediately following OVX decreased communications and social 
interactions between cagemates, as assessed in a test quantifying the number of ultrasonic 
vocalizations emitted, as well as time spent interacting with one another. I interpret this 
result to mean that the E2 animals had improved social memory. In MAT rats gene 
expression of the neuropeptides (Oxt, Avp, Oxtr, Avpr1a) involved in regulating social 
behavior were also greater in the BNST, MeA, and SON of rats treated with estradiol 
 vii 
compared to vehicle. Because menopause typically happens at middle age, I conducted a 
similar experiment in middle-aged rats to assess the influence of estradiol deprivation or 
replacement in aging rats. Aging animals were behaviorally characterized twice (at 3 and 
6-months), groups were given different timing and duration of estradiol or vehicle 
treatments as a model for the WHI. Similar to the MAT animals, the estradiol-treated AG 
rats called less than their vehicle counterparts during an ultrasonic vocalization test 
conducted at the 3-month testing period. However, at the 6-month testing period no 
differences were observed, which could be the result of aging. Oxt, Oxtr, Avp and 
Avpr1a showed unique gene expression patterns that were dependent upon the timing and 
duration of estradiol in a region-specific manner in the AG rats. Most genes were up-
regulated by estradiol treatment, irrespective of timing or duration. Overall this work may 
benefit the field of women’s health through new knowledge on consequences of age, and 
the timing and duration of estrogen treatment, on the social brain and behavior. 
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CHAPTER 1: GENERAL INTRODUCTION 
 
Reproductive aging in females is highly variable in mammalian species. In 
humans, reproductive aging is a continuous process that begins at birth, due to a finite 
number of ovarian follicles, and extends through the menopausal transition when the 
follicular reserve is entirely depleted. The loss of follicles during this perimenopausal 
period causes a profound decrease in the ovarian steroid hormones, especially estradiol 
and progesterone. These changes lead not only to physiological symptoms but also to 
psychological changes.  
Currently the mechanisms behind the reproductive senescence process are not entirely 
understood. Reproductive senescence in mammals involves changes to all three levels of 
the reproductive axis, which comprises the brain (especially hypothalamus), anterior 
pituitary gland, and ovaries. The ovarian hormonal changes during menopause are 
sometimes associated with an array of behavioral, psychological, and neurological 
symptoms. For example, a subset of perimenopausal women report increased anxiety, 
depression and lack of interest in social interaction (Freeman et al., 2004; Schmidtet et 
al., 2004; Bromberger et al., 2011). Understanding how the hormonal changes that are 
occurring during this transition cause behavioral changes is a growing area of research. 
This introduction will provide a brief background on the physiological and psychological 
changes that occur during aging and reproductive senescence in mammalian species. 
Also, part of the introduction is dedicated to describing behavioral tasks that are used to 
evaluate social behavior in animal models.  
 2 
MENOPAUSE  
Menopause in women 
In women the end of reproductive aging is marked by the transition to menopause, 
during which neurobiological and peripheral systems begin to experience profound 
changes. All women will experience menopause, either naturally or surgically. The 
perimenopausal transition typically occurs during the 5th decade of life (Wise et al., 
2002). A women’s reproductive life can be subdivided into 3 phases. The first, 
premenopausal, is the period when a woman experiences regular menstrual cycles. The 
second phase is referred to as perimenopausal, the transition period during which women 
begin to have irregular menstrual cycles. Lastly there is the postmenopausal phase, 
defined as one year past the last menstrual cycle. It is typically during the perimenopausal 
period and the first few years of the postmenopausal phase that women experience 
menopausal neurobiological symptoms, particularly vasomotor dysfunction (hot flashes), 
insomnia and other sleep disturbances, mood changes, as well as affective and cognitive 
changes (Nelson, 2008; Benedetti et al., 2001). It is the hot flashes in particular that lead 
women to seek hormone replacement to improve quality of life. 
Though the endocrinology of the menopausal transition is not yet completely 
understood, each level of the hypothalamic-pituitary-gonadal axis (HPG axis) plays a 
significant role in this process (Nelson et. al., 1995, Wise et. al., 1996). The ultimate 
marker of menopause is the depletion of ovarian follicles that leads to low levels of 
circulating estradiol (Saal et al., 1994). However, the transition to menopause is a gradual 
process. Gonadotropin-releasing hormone (GnRH) neurons in the hypothalamus regulate 
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both follicle stimulating hormone (FSH) and luteinizing hormone (LH) concentrations; 
FSH is also regulated by ovarian inhibins and activins (Maffucci and Gore, 2006; Yin 
and Gore, 2006; Padmanabhan & Sharma, 2001). Elevated levels of FSH as well as 
decreased levels of inhibin B and anti-Mullerian hormone are thought to be indicators for 
the start of the transition from premenopausal to perimenopausal (Reame et al., 1998; 
Sowers et al., 2008). As women age pituitary gonadotropin secretion changes lead to an 
increase in serum FSH and eventually elevated levels of basal LH (Fitzgerald et al., 1998; 
Morrison et al., 2006). These elevations are due to a loss of negative feedback from 
declining ovarian estrogens and progesterone (Kermath & Gore, 2012). As the transition 
progresses, ovarian follicular depletion takes place, which cause fluctuations in ovarian 
hormones such as estrogens and progesterone. Early in the perimenopausal transition 
women can have elevated estradiol levels (Santoro, 2005). However, as the ovarian 
follicles decline through the transition women begin to experience periods of severe 
fluctuations of estrogen and progesterone, leading to the low levels associated with the 
postmenopausal phase (Hall, 2004; Morrison et al., 2006). Levels of other hormones such 
as androgens and growth factors produced by the ovary also decline (Burger et al., 2000; 
Davison et al., 2005). Although this description applies to women who experience 
menopause naturally, approximity one-quarter of a million women in the U.S. undergo 
surgical menopause by hysterectomy and/or oophorectomy (Henderson & Sherwin, 
2007). In these women the neuroendocrine changes due to hormone deprivation occur 
much more precipitously, which can lead to more severe menopausal symptoms (Finch et 
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al., 2011). Table 1.1 shows a break down of the stages of the natural menopausal 
transition. 
 
 
Table 1: Phases of reproductive aging in women 
This table demonstrates some of the changes that women experience during the 
menopausal transition.  Parts of this table were adapted from the 2012 STRAW report on 
the stages of reproductive aging by Harlow and colleagues.  
 
Rodent models of menopause 
The use of animal models to study the effects of menopause and to identify 
potential therapeutic treatments of adverse symptoms is vital for improving women’s 
health. Studying reproductive aging in women is particularly difficult because it typically 
requires longitudinal work often over months or years. In addition it is not possible to 
examine the molecular and cellular changes that occur in the brain during menopause in 
anything other than postmortem tissue. The use of animals is also beneficial because 
Premenopausal Perimenopausal Postmenopausal
Early Late Early Late Early Late
Menstrual Cycle 
Duration Variable Variable Variable ~1 - 3 years ~2 - 6 years Until death
Regular
Small
Changes in 
Flow & Length
Irregular
Longer length 
between cycles 
Greater fluctions
in flow
Periods of 
amenorrhea 
Transition after 
1 year of 
amernorrhea
None None 
Levels of E & P
Regular
Fluctuations 
from 
High to low 
Fluctuations 
from 
High to low 
Dramatic 
 Fluctuations 
Low
Very Low Very Low
Menopausal
Symptoms No No No Yes Yes Variable
Phases
Table 1.1
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researchers are able to control experimental variables that cannot be controlled in 
humans. The two most commonly used animals to study this topic are non-human 
primates and rodents. Research using both of these species has contributed to a better 
understanding of how the endocrine system changes with age and loss of sex steroid 
hormones as well as mechanisms involved in behavioral and cognitive changes. 
Unfortunately primate studies have many of the same problems as work in humans. 
Menopause in the most common monkey models, e.g. rhesus macaques, does not happen 
until animals are nearly 30 years of age. Not only are these animals difficult to obtain; the 
work can be prohibitively expensive. 
 Therefore, rat models, while differing in some aspects of reproductive aging from 
humans, provide several advantages. The HPG axis in rats is similar to that of humans in 
many ways and is quite comparable in neuroendocrine changes that occur during the 
reproductive aging process (Gore, 2002). One major difference is that rats do not 
experience ovarian failure; rather, they undergo neuroendocrine changes at middle age 
that lead to a loss of drive from hypothalamus to pituitary to ovary. More specifically, at 
around 11-12 months of age rats begin to have irregular cycles, with estrous cycles 
transitioning from the typical 4-5 day pattern to a pattern of irregular cycling. Eventually, 
rats stop having estrous cycles altogether and either present as persistent estrus or diestrus 
(Kermath & Gore, 2012). Rats do not see a drastic loss of steroid hormones like women 
do during their transition, which can limit the utility of rodents as a model of natural 
menopause. Therefore, investigators have turned to a model of surgical menopause, using 
ovariectomy (OVX). The OVX model mimics the dramatic loss of ovarian follicles and 
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ovarian hormones that are seen in women who experience menopause by hysterectomy 
and/or oophorectomy. This model has proven valuable in understanding the role of 
steroid hormone loss on vascular function, osteoporosis/osteopenia, cognitive decline, 
affective disorders and social behavior (Castillo et al., 2005; Perez-Martin et al., 2005; 
Namkung-Matthai et al., 2001; Stoffel & Craft, 2004; Garcia et al., 2016).  
 
THE WOMEN’S HEALTH INITIATIVE (WHI)  
In 1991 the National Institutes of Health started a research program called the 
Women’s Health Initiative (WHI). The WHI lasted 15 years and was created in order to 
address the major causes of death, disability and poor quality of life in postmenopausal 
women. It is considered one of the largest randomized clinical studies to date and also 
one of the most controversial (Harman et al., 2006; Bestul et al., 2004; Brown, 2012). 
The WHI’s clinical trial had three components that focused on hormone replacement 
therapy (HRT), dietary modification, or calcium/vitamin D supplementation. I will limit 
this section to the clinical trial, designed to study the effects of HRT on cardiovascular 
disease, osteoporosis, breast cancer, and cognition. Women with a uterus were put into 
the estrogen plus progesterone study in which they were given a daily estrogen 
[conjugated equine estrogen (Premarin)] plus progesterone [medroxyprogesterone acetate 
(Prempro)] tablet, or a placebo (Rossouw et al., 2002). Women without a uterus were put 
into the estrogen-alone study and were given either daily estrogen [conjugated equine 
estrogen (Premarin)] or placebo tablet (Anderson et al., 2004). Both the estrogen alone 
and the estrogen plus progesterone arms of the study were terminated early because the 
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studies found small but significantly increased risk of stroke, breast cancer, coronary 
heart disease, and blood clots (Alving, 2004).  
The termination of the WHI left women and physicians with questions about 
whether, when, and for how long to take hormone treatments for menopausal symptoms. 
Though the WHI initially reported that there was a small but significant increase in 
adverse incidents in women taking hormone therapy, reanalysis suggested that there 
might be a critical window post-menopause during which hormone treatment is beneficial 
to neurobiological and other health-related endpoints. This is also supported by a limited 
amount of animal research showing that the timing of hormone treatment relative to OVX 
has significant effects on neurobiological endpoints, shown to date for basal forebrain 
cholinergic functions, spatial memory, hippocampal spine maintenance, and gene 
expression of NMDA receptors in the hypothalamus and hippocampus (Neal-Perry et al., 
2005, Ottem et al., 2004, Chakraborty et al., 2003, Maffucci et. al., 2009). Therefore, it is 
critical to understand the risks and benefits of estrogen treatments in the context of timing 
and duration for women to be able to make informed decisions and to improve quality of 
life.  
SOCIAL BEHAVIOR  
 
 Social behavior is an area of research that is understudied in the context of 
menopause and HRT despite evidence that perimenopausal women experience increased 
anxiety, depression, and decreased desire to interact socially (Uguz et al., 2011; Deeks 
and McCabe, 2004; Lanza di Scalea et al., 2012; Schmidt et al., 2000). We know from 
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previous literature that estrogens, especially estradiol (E2), regulate these behaviors in 
animals as well as women (de Kloet et al., 2005; Klenerova et al., 2009; Meyer-
Lindenberg et al., 2011; Rubinow, Schmidt & Roca, 1998). The use of animal models of 
menopause can provide a deeper insight into how sex steroid hormones regulate social 
behavior, and help determine underlying mechanisms involved in behavioral regulation. 
This section will cover the literature on the neurobiology of social behavior and current 
behavioral test used to examine social behavior in animals. Later in this chapter, I will 
review the limited research that has been conducted examining the effects of age on 
social behavior as well as estrogen. 
 
Neurobiology of social behavior: Oxytocin, vasopressin, and their receptors  
The literature examining the neurobiology of social behavior is primarily based 
on animal models, although there are a growing number of human studies. This section 
will focus on the neurobiology of social memory/recognition and social interaction based 
on the literature from mice, rats and humans.   
 Oxytocin (Oxt) and vasopressin (Avp) are two neuropeptides that have been 
extensively studied for their roles in social behaviors in animals and humans. In most 
mammalian species Oxt and Avp are synthesized in the magnocellular neurons of the 
supraoptic nucleus (SON) and the paraventricular nucleus (PVN) of the hypothalamus. 
These neurons project to the posterior pituitary where they are released into the 
bloodstream to regulate water and electrolyte balance, milk letdown during lactation, and 
uterine contractions during parturition. In addition to these peripheral actions, Oxt and 
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Avp neural fibers project widely within the central nervous system (CNS). In rats and 
humans, Oxt is also produced in the parvocellular neurons of the PVN, which project to 
the olfactory bulb, dorsal and ventral hippocampus, the amygdala, the substania nigra, 
and nucleus of solitary tract (Buijs, 1978; Sofroniew, 1980; Swanson & Kuypers, 1980; 
Rinaman, 1998). In mice Oxt production has also been found in the bed nucleus of the 
stria terminals (BNST), medial preoptic area (mPOA), and the amygdala (Castel & 
Morris, 1988; Jirikowski et al., 1990; Wang et al., 1996). There are also Avp producing 
neurons in the POA, anterior hypothalamus, BNST, and medial amygdala (MeA) 
(Sofroniew, 1983; De Vries & al-Shamma, 1990; Moore & Lowry, 1998).  
 Actions of Oxt and Avp are mediated by specific receptors. Oxytocin receptor 
(Oxtr) mRNA and binding sites are abundant in the CNS, including in the PVN, MeA, 
BNST, ventromedial hypothalamus (VMH), central amygdala (CeA), shell of the nucleus 
accumbens, and the ventral subiculum of the hippocampus (Brinton et al., 1984; De Kloet 
et al., 1986; Tribollet et al., 1988; Tribollet et al., 1990; Yoshimura et al., 1993; 
Clipperton-Allen et al., 2012). Unlike Oxt, which has only one receptor, three receptors 
have been identified for Avp. The two Avp receptors involved in social behavior are 
vasopressin receptor 1a (Avpr1a) and vasopressin receptor 1b (Avpr1b); the third 
receptor vasopressin receptor 2 (Avpr2) is not abundant in the CNS. Avpr1a, the most 
abundant of the Avp receptors in the CNS, is detected in the olfactory bulb, 
hippocampus, suprachiasmatic nucleus (SCN), PVN, SON, amygdala, arcuate nucleus 
(ARC), substantia nigra, and nucleus of the solitary tract (Ostrowski et al., 1994; Szot et 
al., 1994; Arakawa & Deak, 2010). Avpr1b is predominately found in the anterior 
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pituitary, hippocampus (CA2 region), and the anterior amygdala (Young et al., 2006). 
These different populations and projections likely represent diverse actions of these 
neuropeptides on behaviors and neurobiological functions. 
 Studies in rats, mice and humans have demonstrated that Oxt, Avp, and their 
receptors play a significant role in regulating aspects of social behaviors such as social 
recognition and social interaction. If a male rat is exposed to a juvenile conspecific, and 
then given a low dose intracranial administration of Oxt 5 minutes following the first 
encounter, this leads to the experimental rat spending less time investigating the same 
juvenile conspecific during the second exposure 120 minutes later (Benelli et al., 1995). 
Both male and females also show impaired social recognition if given an Oxt antagonist 
(Benelli et al., 1995; Engelmann et al., 1998; Popik & Vetulani, 1991). Male and female 
rats also show increased social recognition when given peripheral injections of Avp 
(Bluthe et al., 1990; Bluthe and Dnatzer, 1990). However, research looking at the effects 
of Avp antagonist found that it impaired social recognition in female rats but not male 
rats (Englemann et al., 1998; Bluthe et al., 1990; Bluthe and Dnatzer, 1990). Studies have 
found that Avp is mainly responsible for male-typical social behaviors such as aggression 
and reproduction (Donaldson and Young, 2008). Research done using Oxt (OxtKO), Oxtr 
(OxtrKO), and Avpr1a (Avpr1aKO) knockout mice has illustrated how important these 
peptides are for social recognition. OxtKO, OxtrKO, or Avpr1aKO mice do not habituate 
to the repeated presentation of a familiar mouse unlike their wild-type counterparts 
(Choleris et al., 2003; Ferguson et al., 2000; Lee et al., 2008; Takayanagi et al., 2005; 
Bielsky et al., 2004). OxtKO and OxtrKO mice cannot distinguish between a familiar 
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mouse and a novel mouse, which illustrates a lack of social recognition (Takayanagi et 
al., 2005; Choleris et al., 2006). All three types of knockout mice have impaired social 
interaction (Egashira et al., 2007; Choleris et al., 2006; Pobbe et al., 2012).  
 Though the literature is more limited when it comes to research on Oxt and Avp 
in human social behavior, there are some studies demonstrating that these peptides do 
play such a role. In male and female adults Oxt has been found to increase approach 
behavior and positive affect, which leads to higher levels of trust (Heinrichs & Domes, 
2008; Kosfeld et al., 2005). The authors speculated that this result was attributable to a 
reduced neuroendocrine stress response as well as through blockade of anxiety (Heinrichs 
& Domes, 2008). Trust is an important aspect of social affiliation and social approach in 
humans. A landmark study by Kosfeld and colleagues (2005) demonstrated that a single 
dose of intranasal Oxt in adult human subjects significantly increased trust in a trust game 
that required social interaction. 45% of the subjects who received Oxt reached the 
maximum trust level compared to the 21% in the placebo group. This study supports 
research that has been conducted in animals, that Oxt is necessary for prosocial approach 
behavior (Heinrichs & Domes, 2008). Additionally, Heinrichs and colleagues (2003) 
found that the combination of intranasal Oxt plus social support reduced cortisol levels as 
well as decreased anxiety and increased calmness in healthy men. In a double-blinded 
fMRI study in humans researchers found that intranasal Oxt led to increased tolerance to 
betrayal of trust as well as reduced activation in the amygdala, midbrain regions, and the 
dorsal striatum (Baumgartner et al., 2008). As in rodents, the effects of Avp on social 
behavior in humans appears to be sex specific. Intranasal Avp administration led women 
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to have increased perceived friendliness of a same-sex conspecific while in men it 
decreased this perception (Thompson et al., 2006).  A study using fMRI by Zink and 
colleagues (2010) found that intranasal Avp had modulatory effect on the amygdala-
medial prefrontal cortex circuit, with changes between the subgenual and supragenual 
cingulate cortices. It has been postulated that these changes reflect disinhibition of the 
amygdala because research has demonstrated that the medial prefrontal cortex regulates 
amygdala activity via negative feedback (Quirk et al., 2003). 
 
Behavioral tests to study social memory and social interaction in rodents 
 The emergence of standardized behavioral testing in rodents has improved our 
understanding of how drugs, genetics, and various aspects of the environment affect 
specific behaviors, including learning, memory, depression, anxiety, mating, aggression, 
and social behavior. This section will focus on common behavioral paradigms and 
apparati used to study social memory and social interaction. In addition, I will discuss a 
novel paradigm designed to look at familiar female-to-female social interaction as well as 
how ultrasonic vocalizations can be used to measure social memory. 
 Tests of social memory and social interaction typically use either the habituation-
dishabituation paradigm or a social discrimination paradigm. In the habituation-
dishabituation, the experimental animal is presented with a novel conspecific either for a 
single trial (Thor & Holloway, 1982; Thor, 1980) or over multiple trials (Sánchez-
Andrade & Kendrick, 2011; Choleris et al., 2003; Choleris et al., 2007; Spiteri & Ågmo, 
2009). The conspecific is then removed for a period of time (minutes, hours, or days) and 
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then reintroduced to the experimental animal after the allotted time. If the animal has 
habituated to the conspecific, meaning it no longer views it as a novel, it should show 
decreased social interaction compared to its initial interaction with the conspecific. Then, 
the first conspecific is removed and a novel one is put in its place; this typically results in 
increased social interaction, termed dishabituation.  
 The social discrimination paradigm has two steps. In the first step the 
experimental animal is either presented with one conspecific or two conspecifics at the 
same time for a specified duration (single trial or over multiple trials). The conspecific or 
conspecifics are then removed for a period of time (minutes, hours, or days). For step 2 
the familiar conspecific is reintroduced to the experimental rat along with a novel 
conspecific after having been separated for a specific duration of time (Reilly et al., 2015; 
Choleris et al., 2006; Engelmann et al., 1995). If the experimental animal spends more 
time with the novel conspecific it is demonstrating social memory because rats are 
inclined to investigate novel animals or objects over familiar ones.  
A novel paradigm for studying social memory is proposed in this dissertation. The 
first step is to pair-house rats of the same sex, age, and hormone status for an allotted 
amount of time (for this dissertation, either 3 or 6 months). In step 2 the cagemates are 
separated from each other for a set amount of time, in my case, 1 week. Then, similar to 
the habituation-dishabituation paradigm, the cagemates are reintroduced to each other 
and social interaction is observed using a setup similar to the social discrimination 
paradigm. After the 1-week separation period, one of the cagemates is chosen to be the 
experimental rat and given a choice between her cagemate and a novel conspecific of the 
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same sex, age, and hormone status. Both of these paradigms allow for evaluation of 
social memory and social interaction.   
 Social memory tests typically take place in either the experimental animal’s home 
cage (Bielsky et al., 2004; Ferguson et al., 2000), a neutral open field box (Gregus et al., 
2005; Tõnissaar et al., 2004), or a sociability 3-chamber apparatus (Reilly et al., 2015; 
Crews et al., 2012; Felix-Ortiz & Tye, 2014; Riedel et al., 2009). When using the 
experimental animal’s home cage or the open field box, the experimental and the 
conspecific(s) are allowed to freely interact with each other, which is not the case with 
the sociability apparatus. The difference between using the experimental animal’s home 
cage and the open field box is that the experimental animal has established the home cage 
as its territory and is therefore more likely to show aggression, especially with male 
rodents, or in the resident intruder test (Rammal et al., 2010; Takayanagi et al., 2005). 
Using the open field box the researcher takes away the element of resident territory. The 
sociability test also removes the aspect of resident territory since both the experimental 
animal and the stimulus animal(s) are only habituated to the chambers for a short period 
of time (Reilly et al., 2015; Crews et al., 2012; Felix-Ortiz & Tye, 2014; Riedel et al., 
2009). In this setup the experimental animal is allowed to freely move throughout the 3-
chambers but the stimulus rats are placed into holding cages that only allow for 
interactions such as nose touching and anogenital investigation. The interactions that take 
place using this apparatus ensures that it is being done exclusively by the experimental 
rat.   
 Ultrasonic vocalizations (USVs) are a natural form of communication in rats that 
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have been shown to be effective in measuring aspects of social behavior and in assessing 
affective state. Ultrasonic vocalizations in adults can be broken down into two distinct 
types of calls 22-kHz or 50-kHz. When a rat is exposed to a predator (Blanchard et al., 
1991), pain (Antoniadis and McDonald, 1999; Borta et al., 2006; Wöhr et al., 2005) or 
drug withdrawal (Miczek & Barros et al., 1996;) they emit long 22-kHz USVs, which are 
though to be a reflection of a negative affective state (Antoniadis and McDonald, 1999; 
Borta et al., 2006; Wöhr et al., 2005). Whereas 50-kHz calls are thought to be reflective 
of a positive affective state (Panksepp & Burgdorf, 2003) and are seen during juvenile 
play (Knutson et al., 1998; Lukas & Wöhr, 2015), social exploratory activity (Brudzynski 
& Pniak., 2002), and mating behavior (McGinnis et al., 2003; White et al., 1990). 
Previous research has shown that 50-kHz USVs can be used to study social motivation 
and social interest (Wöhr & Schwarting, 2007; Wöhr & Schwarting, 2009). Resident 
intruder studies have also shown that if a female rat is exposed to the same female 
intruder after separation intervals the resident will emit fewer USVs each time, indicative 
of social memory (D’Amato & Moles, 2001; Moles et al., 2007). In my dissertation, I 
will illustrate how USVs can be used to measure social memory in the context of familiar 
female-to-female interaction. 
 
Social behavior and estrogen  
Though the majority of research in mice and rats exclusively used males, research 
on females has shown that sex steroid hormones such as estrogens and progesterone are 
important for normal social behavior. Estrogen treatment promotes the synthesis of Avp, 
 16 
Oxt and Oxtr mRNA, which decrease significantly after OVX (Patchev et al., 1995; Ho 
& Lee, 1992; Sarkar et al., 1992). Oxytocin mRNA is increased by E2 treatment in the 
POA, and its receptor is increased in the MeA (Patisaul et al., 2003; Quiñones-Jenab et 
al., 1997; Caldwell et al., 1989). Estrogen regulates Oxt and Avp in the SON and PVN 
predominantly through the estrogen receptor beta [(ERβ, Esr2), Winslow and Insel, 2004; 
Hrabovszky et al, 1998] and in the BNST, mPOA, and MeA through both ERβ and 
estrogen receptor alpha [(ERα, Esr1), Axelson and van Leeuwen, 1990; Wang & De 
Vries, 1995; Quinones-Jenab et al., 1997; Bale, Pederson & Dorsa, 1995; Ferguson et al., 
2002]. The fact that Oxt and Avp are modulated by estrogens leads to the hypothesis that 
with age the lack of estrogen may affect Oxt and Avp and in turn affect social behavior 
(Choleris et al., 2004, Ferguson et al., 2002, Winslow and Insel, 2004).  
Previous research using female ERα knockout (ERαKO) and ERβ (ERβKO) 
knockout mice found that each of these lines have impaired social memory and social 
interaction (Choleris et al., 2003; Hlinak, 1993; Egashira et. al, 2007). However, other 
studies found that only the ERαKO mice showed impaired social memory (Sanchez-
Andrade & Kendrick, 2011; Choleris et al., 2006). It has been postulated that this 
discrepancy is due to different experimental protocols such as the type of stimuli used, 
accessibility of social stimuli, testing environment as well as number of trials (Sanchez-
Andrade & Kendrick, 2011). Similar deficits are seen in rats after OVX (Hlinak, 1993; 
Tang et al., 2005), and this is improved by estradiol replacement therapy (Hlinak, 1993; 
Tang et al., 2005) or estrogen plus progesterone (Spiteri & Agmo, 2009) treatments. As 
additional evidence for estradiol’s roles, female mice have enhanced social recognition 
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during the proestrous phase of their estrous cycle, the stage when estrogens and 
progesterone are high (Walmer et al., 1992; Sanchez-Andrade & Kendrick, 2009). Also, 
when estrogen levels are high during the late phase of pregnancy or during lactation, the 
rats show decreased neophobia to approach pups or lactating nesting material (Numan & 
Sheehan, 1997; Kinsley & Bridges, 1990), and this is seen if OVX rats are given 
hormones to mimic the hormone levels seen during late pregnancy (Fleming et al., 1989).  
 
Social behavior and aging  
As people age social networks begin to narrow, social roles change, negative 
emotions become less frequent and there is an increase in meaningful relationships 
(Charles & Carstensen, 2010; Fung et al., 2001; Birditt & Fingerman, 2003). With older 
age people report lower levels of negative affect (Carstensen et al., 2000; Deiner & Suh, 
1997; Mroczek & Kolarz, 1998) and lower incidents of anxiety and major depressive 
disorder (Piazza & Charles, 2006). After age 60 people often report upturns in depressive 
symptoms (Deiner & Suh, 1997; Haynie et al., 2001; Davey et al., 2004). However, 
during the menopausal transition and during the first few years of menopause women 
experience increased anxiety, depression, and decreased desire to interact socially even if 
no they have no prior history of affective disorders (Uguz et al., 2011; Deeks and 
McCabe, 2004; Lanza di Scalea et al., 2012; Schmidt et al., 2000). Studies examining 
post-mortem human brain tissue found that with normal aging there is an increase in 
numbers of Avp (although not Oxt) expressing neurons, as well as increased nucleolar 
size of these neurons in the SON and PVN of the hypothalamus. These changes are 
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suggestive of increased peptide production and enhanced neurosecretory activity during 
senescence (Swaab et al., 1985; Fliers et al., 1985a; Hoogendijk et al., 1985; Lucassen et 
al., 1993). It is important to note that the changes seen in these studies were only 
observed in tissue from subjects that were 80 years or older. Also, since sample sizes are 
small in these studies they did not separate the subjects by sex. Though a study conducted 
by Ishunina and Swaab (1999) examined the effects of age and sex on vasopressin and 
oxytocin neurons in the SON and PVN in post-mortem human brain tissue. They found 
that older women (>50 years old) had significantly larger Avp cell size than younger 
women (<50 years old), age was also found to correlate with cell size in women. Though 
they did not take into account the women’s hormone status at the time of death or 
whether or not they were taking hormone replacement therapy.  
 Animal studies have also demonstrated brain and behavior changes associated 
with increased age. A study conducted by Salchner and colleagues (2004) found that aged 
male rats (30 months old) spent 75% less time partaking in active social interaction 
compared to young rats (3 months of age). In a study using a rat habituation-
dishabituation paradigm researchers found that during the dishabituation phase there was 
a progressive decrease in time spent investigating a novel rat from 3 to 15 to 22 months 
of age (Guan & Dluzen, 1994). In contrast, Boguszewski and Zagrodzka (2002) did not 
see age related changes in social interaction when they compared young (~4 months) and 
old (~24 months) male rats. To my knowledge there have been no studies to data looking 
at age related changes on social memory or social interaction in female rats. One of the 
aims in this dissertation was to fill this gap in the literature. In addition, the effects of age 
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on the neurobiology involved in regulation social behavior is mixed with some studies 
demonstrating that vasopressin protein and mRNa decrease with age (Dorsa & 
Bottemiller, 1982; Fliers et al., 1985b; Terwel et al., 1992; Balmagiya & Rozovski, 1983) 
while others have found that it increases (Rodeck et al., 1960; Watkins & Choy, 1980; 
Sladek et al., 1981). Though similar to the human literature rodent’s studies do not see 
any effects of age on oxytocin protein or mRNA (Fliers et al., 1985b; Keck et al., 2000).  
Both humans and rodents studies have reported elevated basal AVP plasma levels with 
age (Miller, 1987; Terwel et al., 1992; Johnson et al., 1994).   
 
SUMMARY AND CONCLUSION 
 Overall, it is apparent that age and the loss of ovarian hormones have significant 
impacts on the brain and behavior in both humans and rodents. Unfortunately, animal 
models looking at the role of estradiol on the social brain and behavior have focused on 
short-term treatment and used relatively young animals. Since the loss of estrogen 
happens later in life and is influenced by the aging process it is vital that research be done 
using middle-aged or aged animals. In addition, it is important for clinical and basic 
research to address the findings and limitations of the WHI so that women and physicians 
can be better informed about the risk and benefits of HRT. A rigorous test of the “critical 
window” hypothesis is badly needed and is one of the main focuses of my dissertation.  
 
SUMMARY OF DISSERTATION EXPERIMENTS 
This dissertation focuses on the effects of estrogen therapy on social behaviors, 
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and on molecular properties of brain regions involved in these behaviors such as the 
MeA, PVN, SON, BNST, and the PFC. These interconnected regions express estrogen 
receptors (ERα and ERβ), and hormones that are critical to social behaviors such as 
oxytocin and vasopressin, along with their receptors. However, little is known about the 
relationship between estrogen replacement therapy, aging, and social behaviors in 
women. Clinical studies have shown that menopause can negatively affect a woman’s 
social interaction and personal relationships. However women who have a strong support 
system (close friendships and supportive families) do not report having increased 
depression and/or anxiety during the different stages of menopause. Insights into the 
mechanistic underpinnings of the relationship between estrogen replacement therapy and 
social behavior are lacking, underscoring the need for animal models. Therefore, the goal 
of this dissertation is to help fill this gap and to gain a better understanding of how timing 
and duration of hormone therapy can affect social interactions, together with underlying 
mechanistic effects on neurobiological systems.  
Proposed experiments will utilize female rats at different life stages [young adult 
(mature) or aging (AG)], OVX to remove ovarian hormones, and administered 
physiological E2 or vehicle with different timing and durations as a model for informing 
hormone treatments post-WHI.  
 
Overarching Hypothesis 
Test the hypothesis that the timing and duration of estrogen therapy affects social 
behaviors through biological and mechanistic changes that occur in selected brain regions 
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as a function of aging, estradiol treatment, and their interactions. 
 
Chapter 2 tested the hypothesis that timing and duration of estradiol treatment relative 
to deprivation (OVX) affects the expression of genes in hypothalamus (PVN & SON) of 
mature-adult (MAT) and aging (AG) rats.  
 
I examined the neural circuits that underlie social behaviors in order to gain 
mechanistic insight into the molecular changes that occur during aging and in response to 
timing/duration of E2 treatment. This chapter is focused on gene expression work, 
looking at specific brain regions (SON & PVN) that are important in social behavior. My 
selected targets genes were OT and AVP, their receptors (Oxtr, Avpr1a), and ERα.  
 
Chapter 3 tested the hypothesis that estradiol treatment relative to deprivation has 
significant effects on social behavior and gene expression of mature-adult female rats. 
 
In this chapter I specifically used mature-adult rats, to develop and refine my 
novel social behavioral tests. Rats were behaviorally characterized using an ultrasonic 
vocalizations (USVs) test and a test of sociability. In all cases, the social partners were 
the experimental rat’s cage-mate (same age/treatment group). After behavioral testing, 
rats were euthanized, brains were dissected, and used for gene expression with targets 
chosen based on their role in social behavior, estrogen regulation, and aging.  
 
 
Chapter 3 tested the hypothesis that estradiol treatment relative to deprivation has 
significant effects on social behavior and gene expression of aging female rats. 
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In this chapter aging female rats were used in order to examine the effects of 
timing and duration of estradiol treatment. Rats were behaviorally characterized using an 
ultrasonic vocalizations (USVs) test and a test of sociability. Behavioral testing took 
place at two separate time points the first was after 3-months of treatment and the second 
after 6-months of treatment. In all cases, the social partners were the experimental rat’s 
cage-mate (same age/treatment group). After behavioral testing, rats were euthanized, 
brains were dissected, and used for gene expression with targets chosen based on their 
role in social behavior, estrogen regulation, and aging.  
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CHAPTER 2: TESTING THE CRITICAL WINDOW OF 
ESTRADIOL REPLACEMENT ON GENE EXPRESSION OF 
VASOPRESSIN, OXYTOCIN, AND THEIR RECEPTORS, IN THE 
HYPOTHALAMUS OF AGING FEMALE RATS. 
 
The Text in this section is excerpted from Garcia, A. N., Depena, C. K., Yin, W., & Gore 
A.C., Molecular and Cellular Endocrinology 419: 102-112 (2016), with permission from 
the journal.  
 
ABSTRACT 
 
The current study tested the “critical window” hypothesis of menopause that 
postulates that the timing and duration of hormone treatment determine their potential 
outcomes. Our focus was genes in the rat hypothalamus involved in social and affiliative 
behaviors that change with aging and/or estradiol (E2): Avp, Avpr1a, Oxt, Oxtr, and Esr2 
in the paraventricular nucleus (PVN) and supraoptic nucleus (SON). Rats were 
reproductively mature or aging adults, ovariectomized, given E2 or vehicle treatment of 
different durations, with or without a post-OVX delay. Our hypothesis was that age-
related changes in gene expression are mitigated by E2 treatments. Contrary to this, PVN 
Oxtr increased with E2, and Avpr1a increased with age. In the SON, Avpr1a increased 
with age, Oxtr with age and timing, and Avp was by duration. Thus, chronological age 
and E2 have independent actions on gene expression, with the “critical window” 
hypothesis supported by the observed timing and duration effects. 
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INTRODUCTION 
Menopause is the physiological cessation of ovarian function during which 
menstrual cyclicity ceases and concentrations of ovarian hormones such as estrogens and 
progesterone decline. Hormone replacement therapy (HRT) is currently the most 
commonly used therapy to treat menopausal symptoms. However, since the termination 
of the Women’s Health Initiative (WHI) study of conjugated equine estrogens and 
medroxyprogesterone acetate treatment, many women have been left asking questions 
about whether, when, and for how long to take hormone treatments for menopausal 
symptoms. The WHI initially reported that there was a small but significant increase in 
adverse incidents in women taking hormone therapy (Rossouw et al., 2002; Manson et 
al., 2013). Reanalysis suggested that there might be a critical window post-menopause 
during which hormone treatment is beneficial to neurobiological and other health-related 
endpoints in women (Klaiber et al., 2005; Bhupathiraju & Manson, 2014). Therefore, it is 
necessary to understand the risks and benefits of estrogen treatments in the context of 
timing and duration for women to be able to make informed decisions and to improve 
quality of life. 
In addition to hot flashes, neurobehavioral changes such as anxiety and depression 
increase at menopause in humans, which can lead to social isolation and impact the 
quality of life (Uguz et al., 2011; Deeks & McCabe, 2004; Lanza di Scalea et al., 2012). 
Oxytocin (Oxt) and vasopressin (Avp) are modulators of these behaviors in mammalian 
species  [de Kloet et al., 2005 (mice); Klenerova et al., 2009 (rat); Meyer-Lindenberg et 
al., 2011 (human); Lim & Young, 2006 (voles)]. Both of these neurohypophyseal 
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peptides are synthesized in the supraoptic nucleus (SON) and the paraventricular nucleus 
(PVN) of the hypothalamus.  
Vasopressin and oxytocin neurons are regulated by estrogens, predominantly 
through the estrogen receptor beta (ERβ) that is the dominant ER in these regions, as 
demonstrated in knockout mice (Winslow & Insel, 2004) and by gene and protein 
expression in rats (Hrabovszky et al, 1998). ERβ protein and mRNA is also colocalized 
with oxytocin- and to a lesser extent with vasopressin-expressing neurons of rats and 
mice (Hrabovszky et al., 1998; Alves et al., 1998; Patisaul et al., 2003). However, the 
effects of estradiol on the regulation of vasopressin and oxytocin are mixed, and most 
studies utilized short-term treatment regimes. Some studies showed up-regulation  [Roy 
et al., 1999 (mRNA, monkey); Patisaul et al., 2003 (mRNA & protein, mouse)], others 
down-regulation [Shughrue et al., 2002 (protein, rat); Van Tol et al., 1988 (mRNA, rat); 
Nomura et al., 2002 (mRNA & protein, mouse)], and still others no effect [Peter et al., 
1990 (mRNA, rat); Rhodes et al., 1981 (protein, rat); Akaishi & Sakuma, 1985 (protein, 
rat)] of estradiol treatment. This inconsistency in results was part of our motivation for 
conducting the work, and to hypothesize that the effects of estrogen would be influenced 
by different timings and durations of treatment.  
Along with oxytocin and vasopressin, we also selected Oxtr and Avpr1a gene 
expression as endpoints because of their role in mediating effects of their respective 
nonapeptides on social behaviors such as anxiety and depression (Young, 1999; Bielsky 
et al., 2004; Sala et al., 2011). Previous studies using RT-PCR, in situ hybridization, 
immunohistochemistry and electrophysiology have shown that mRNA and protein of the 
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vasopressin receptor 1a and the oxytocin receptor are expressed in the SON and PVN of 
rats (Hurbin et al., 1998, 2002; Gouzènes et al, 1999; Yoshimura et al., 1993). This study 
was designed to help fill the gap in research and to gain mechanistic insight into the 
molecular changes that occur during aging and in response to differential modes of 
treatment to assess the effects of timing and duration of E2. By studying outcomes of Avp, 
Avpr1a, Oxt, Oxtr and Esr2 in the PVN and SON of the hypothalamus, we can have a 
better understanding of the neural substrates involved in social behavior as a basis for 
future work testing the “critical window” hypothesis on the behaviors themselves.  
 
MATERIALS AND METHODS 
Animals and Husbandry 
All animal procedures were conducted in accordance with The Guide for the Care 
and Use of Experimental Animals following protocols approved by The University of 
Austin IACUC committee and NIH standards. Female Sprague Dawley rats (Harlan) 
were purchased as reproductively mature adults (MAT, ~3 months, sexually naïve) or 
aging adults (AG, ~11 months, retired breeders). These animals are the same as those 
used in a separate study (Yin et al., 2015) for analyses of different brain regions. Upon 
arrival, rats were pair housed on a 12-hour light, 12-hour dark cycle (lights on at 0700) 
and received water and food ad libitum. They were allowed to acclimate to the room for 
two weeks prior to surgery during which time estrous cyclicity was monitored daily by 
vaginal lavage of sterile saline. Only females with regular 4-5 day cycles were used. All 
rats received ovariectomy surgery under isofluorane inhalation anesthesia. A single 
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injection of Rimadyl (5 mg/kg) was given at the start of surgery. Bilateral dorsolateral 
incisions were made through the skin, muscle, and peritoneum, and the ovaries were 
ligated and removed. Muscles were sutured and wound clips used to close the skin.  
Animals were randomly assigned to one of eight treatment groups as illustrated in 
Figure 1 to test different timings and durations of hormone treatment based on those used 
in the WHI, in which the women experienced an average 12-year delay in treatment 
relative to the last menstrual period. We calculated based upon the rats’ life cycle 
compared to humans, that 3 months to an adult rat is equal to about 5 years in a woman 
(Sengupta, 2013; Quinn, 2005). Capsules containing either 100% cholesterol (Veh) or 5% 
17β-estradiol / 95% cholesterol (E2) were implanted subcutaneously between the shoulder 
blades at the time of surgery. Because the aim of this study was to address and reevaluate 
limitations of the WHI, we chose to use continuous exposure to E2 at a physiologically 
relevant dosage to mimic the type of treatment given in the Estrogen-alone WHI studies 
(The Women’s Health Initiative Study Group, 1998). This treatment regime is clinically 
relevant, as continuous E2 treatments are still in common use for subsets of 
postmenopausal women.  
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Figure 1.1: Treatment groups  
 
The eight treatment groups are shown that were used to test age, and duration and timing 
of E2 treatment. Reproductively mature adult (MAT) were 4 months old at the time of 
ovariectomy (OVX) surgery and aging rats (AG) were 11 months old at the time of OVX, 
and received either vehicle (cholesterol; VEH) or 17β-estradiol capsule implantation at 
the time of surgery. Both groups of MAT rats and two groups of AG rats received 
treatment for a duration of 3 months (Groups 1-4). Two groups of AG rats received 
treatment for duration of 6 months (Group 5 & 6). There were two AG “switch” groups 
that received either VEH or E2 initially at the time of OVX and were switched to the 
opposite treatment after 3 months, and continued on the new treatment for a 3-month 
duration (Group 7 & 8). This model enabled us to differentiate effects of age (Groups 1-
4), duration (Groups 3-6) and timing (Groups 5-8). 
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Tissue processing  
 Rats were euthanized 3 or 6 months after OVX and hormone treatment, when 
mature adults (MAT) were ~7 months, and aging adults (AG) were ~14 or ~17 months of 
age. All animals were weighed and euthanized by rapid decapitation starting at 1330 
hours with the last animal killed not later than 1600 hours; therefore they were all killed 
during the lights on period. Although there is a diurnal rhythm of vasopressin gene 
expression in the SCN, previous studies have shown that within in SON and PVN, the 
areas used in the present study, there is no diurnal change in vasopressin or oxytocin gene 
expression in rats (Uhl & Reppert, 1986, Burbach et al., 1988). In addition, when we used 
time of euthanasia as a covariate in statistical analyses, no time of day effect was found. 
Brains were removed and sectioned in 1-mm coronal sections using an ice-cold stainless 
steel brain matrix. Sections were placed into cryogenic storage vials that contained 
RNAlater (Life technologies, Grand Island, NY). Tubes were stored at 4°C overnight, 
then mounted onto chilled slides and placed in a -20°C freezer for storage. Using 
Palkovits punches and the Paxinos and Watson (2009) rat brain atlas (all coordinates are 
based on that atlas), bilateral micropunches were taken under a dissecting microscope. 
The PVN punch (1.22 mm diameter) began rostrally at ~Bregma = -0.84 mm, and 
extended caudally 1 mm. The SON punches (0.96 mm diameter) started rostrally at 
~Bregma = -0.60 mm and extended caudally for 1 mm. The choice of sampling areas was 
based on previous studies showing large concentrations of magnocellular neurons 
containing both vasopressin and oxytocin protein in rats at this range of coordinates 
(Rhodes et al., 1981; Swanson & Sawchenko, 1983). The PVN has several subdivisions 
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(Swanson & Sawchenko, 1983), and the location of our punches includes the part that lies 
ventromedial to the descending column of the fornix between Bregma = -1.44 to -1.56), 
and the lateral magnocellar subdivision (Krieg, 1932; Swanson & Sawchenko, 1983) 
from Bregma = -1.72 to -1.92. Punches for each region were placed in a frozen 
Eppendorf tube for storage at -80°C. At the time of decapitation trunk blood was 
collected and allowed to clot, serum was separated and centrifuged (2300 X g for 5 
minutes) then stored in Eppendorf tubes at -80°C. 
 
Real-time PCR assays 
 RNA was extracted from frozen PVN and SON punches using an Allprep RNeasy 
mini kit (Qiagen, Valencia, California), according to the manufacturer’s protocol. 
Although we started with n=10 rats per group, loss of some tissues during freezer storage 
caused some attrition (a subset of samples were frozen with too much liquid RNAlater 
that made it difficult to visualize brain landmarks; only samples were included with 
which we were confident in the landmarks), resulting in n=7 for most gene assays. After 
extraction the quality of RNA was checked on an Agilent 2100 Bioanalyzer (Agilent, 
Santa Clara, CA) and all RIN values fell in the range of 8.6 to 9.9. The quantity of RNA 
was measured using a GloMax-Multi Detection System (Promega, Madison, WI), and 
ranged from 71 to 741 ng/ul in SON, and from 207 to 1550 ng/ul in the PVN. Using a 
high-capacity cDNA reverse transcription kit (Life Technologies, Grand Island, NY), 
mRNA (PVN 200 ng, SON 150 ng) was converted to single-stranded cDNA. Samples 
were stored at -20°C until use. Quantitative real-time PCR was used to analyze 5 genes in 
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the PVN and 4 genes in the SON: Avp, Oxt, Avpr1a, Oxtr, Esr2 (FAM) in tandem with 
Gapdh (VIC). Esr2 could not be run in SON due to the smaller amounts of RNA 
extracted from this smaller dissection limiting us to 4 genes maximum for analysis. All 
samples were run in triplicates with probe and primer predesigned gene expression assays 
(Life Technologies, Grand Island, NY). Target genes were amplified using Taqman 
universal mastermix (Life Technologies, Grand Island, NY) and detected on a ViiA7 
Real time PCR machine (Applied Biosystems, Life Technologies, Grand Island, NY) 
with the following run parameters: 0°C for 2 minutes, 95°C for 10 minutes, 45 cycles of 
95°C for 15 seconds, and 60°C for 1 minute. Relative expression was determined for 
each sample using the comparative cycle threshold method (Pfaffl, 2001; Schmittgen & 
Livak, 2008). All samples were normalized to the housekeeping gene Gapdh and then 
calibrated to the median δ-cycle threshold of the young 3-month vehicle treated group. 
Any of the triplicates with a value of 2 SD above the mean of an individual animal was 
removed. Samples that amplified at or above 35ct were excluded from analysis.    
 
Gene expression Analysis 
 Expression of each gene was analyzed using SPSS (version 22). For age (groups 
1-4, Figure 1.1), two-way ANOVA was used to analyze the effects of age (MAT vs. AG) 
and hormone (VEH vs. E2). For duration (groups 3-6, Figure 1.1), two-way ANOVA was 
used to analyze effects of treatment duration (3 mo vs. 6 mo) and hormone (VEH vs. E2). 
Interactions among variables were also analyzed. A one-way ANOVA with a Bonferroni 
post hoc was performed to examine the effect of timing (groups 5-8, Figure 1.1).  For all 
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of these analyses, alpha was set at 0.05 and significant main or interaction effects were 
followed by two-tailed independent sample t-tests. Those data that did not pass the 
assumptions of normality and/or variance were transformed using either a square root or 
log transformation. Avpr1a in the PVN and Oxtr in the SON data did not meet 
assumptions even after transformation; therefore a non-parametric analysis was 
performed followed up with Mann-Whitney t-test.  
 
Hormone assays and correlations 
Twelve serum hormones were measured, for which detailed methods and results 
were previously reported on these same rats in a separate study evaluating other 
endpoints (Yin et al., 2015). For the current study, values for serum estradiol (E2), 
progesterone (P4), corticosterone (Cort), brain-derived neurotrophic factor (BDNF) were 
used for correlations with each of the target genes using Pearson’s correlation on raw or 
square-root transformed data when a dataset did not meet assumptions of normality. For 
those data sets that did not meet the assumptions even after transformation, a Spearman’s 
nonparametric correlation was used.  
 
RESULTS 
Gene expression  
Paraventricular nucleus 
 Two genes, Oxtr and Avpr1a, were significantly affected only in comparisons of 
the 3-month treatment groups 1-4 (Figure 1.2). In these animals, there was a main effect 
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of treatment on Oxtr expression. Expression was increased by estradiol compared to 
vehicle in both the 3-month MAT and AG groups, an effect that was not seen in any of 
the 6-month duration groups (Figure 1.2C; p < 0.05). For Avpr1a, there was a significant 
main effect of age. In the comparison of the 3-month post-OVX groups, the AG animals 
had significantly higher gene expression than the corresponding MAT rats, but no 
hormone effects (Figure 1.2D; p < 0.05). There were no effects of age, timing, or duration 
on Oxt, Avp, and Esr2 expression in the PVN (Figure 1.2A, B, E). 
Supraoptic Nucleus  
 Three of the four genes measured, Avp, Oxtr, and Avpr1a, were significantly 
affected, each with a unique expression pattern (Figure 1.3). For Avp, two-way ANOVA 
of Groups 3-6 found no main effects of duration or treatment; however there was a 
significant interaction (p < 0.05). Specifically, Avp was significantly lower in the AG-E6 
than the AG-E3 and AG-V6 (Figure 1.3B; p < 0.05). For Oxtr, a main effect of age was 
found in the 3-month treatment groups (1-4), with levels higher in the AG than the MAT 
rats (Figure 1.3C; p < 0.05). In addition, a timing effect was found for groups 5-8, with 
Oxtr higher in the AG-V3/E3 rats than the AG-V6 or AG-E3/V3 rats. Avpr1a expression 
also had a main effect of age in groups 1-4, with levels higher in the AG than the MAT 
rats (Figure 1.3D; p<0.05). Oxt gene expression was unaffected (Figure 1.3A). 
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Figure 1.2: PVN relative expression data 
Relative gene expression data are shown in the PVN. Note that the scale of the y-axis 
varies depending on the gene. Comparisons of age were made in groups 1-4, duration of 
hormone in groups 3-6, and timing of hormone in groups 5-8. Oxt, Avp and Esr2 were 
unaffected by treatment, age, duration, or timing. For Oxtr there were significant 
hormone effects in the 3-mo treated groups. For Avpr1a, there was a significant age effect 
in those same groups. Data shown are mean + SEM. *, p < 0.05. 
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Figure 1.3: SON relative expression data  
Relative gene expression data are shown in the SON. Note that the scale of the y-axis 
varies depending on the gene. Comparisons of age were made in groups 1-4, duration of 
hormone in groups 3-6, and timing of hormone in groups 5-8. Oxt was unaffected by 
treatment, age, duration, or timing. For Avp the E6 group had significantly higher 
expression than the V6 and E3 group. Oxtr had a significant age effect and a significant 
timing effect; the V3/E3 group had higher expression than the E3/V3 and E6 groups. For 
Avpr1a, there was also a significant age effect in the 3-month treatment groups. Data 
shown are mean + SEM. *, p < 0.05. 
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Correlation results  
 Correlation analysis was used as a hypothesis-generating method to identify 
relationships among genes, and between genes and hormones, as well as a way of 
validating the PCR results.  
 
Gene correlations within the PVN and SON 
No genes in the PVN correlated significantly with any of the genes in the SON, 
but within each region there were positive correlations. Within the PVN, Oxt was 
significantly correlated with Avp (Figure 1.4A), and Oxtr was significantly correlated 
with Esr2 (Figure 1.4B). Within the SON, Oxt was significantly correlated with Avp 
(Figure 1.4C). In addition, Oxtr was significantly correlated with Avpr1a (Figure 1.4D). 
Detailed statistics for all of the gene correlations are provided in Supplemental Table 
S1.1. 
 
Hormone and gene expression correlations 
 Serum hormone concentrations and assay characteristics were reported in a 
companion paper (Yin et al., 2015) and we refer readers to that study for graphic 
presentation. As published, concentrations (means + SEM) used for the correlations were 
as follows for groups 1-8. Estradiol (pg/ml): 1) 24 + 3; 2) 105 + 11; 3) 20 + 1; 4) 63 + 7; 
5) 17 + 2; 6) 63 + 5; 7) 64 + 6; 8) 20 + 2. The estradiol treated groups all had 
significantly higher E2 concentrations than their matched vehicle groups. BDNF (ng/ml): 
2) 4.8 + 0.4; 2) 3.2 + 0.3; 3) 3.4 + 0.3; 4) 3.2 + 0.4; 5) 4.4 + 0.7; 6) 2.7 + 0.3; 7) 2.6 + 0.3; 
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8) 4.0 + 0.6. The estradiol groups had lower BDNF concentrations than their matched 
vehicle groups, and there was a trend for an age-related decrease in BDNF. 
Corticosterone (ng/ml): 1) 36 + 8; 2) 105 + 21; 3) 37 + 9; 4) 47 + 11; 5) 53 + 9; 6) 65 + 8; 
7) 59 + 7; 8) 39 + 8. Reproductively mature rats had significantly higher corticosterone 
concentrations in the E2 group compared to vehicle, but there were no such effects in the 
aging rats.  Progesterone (ng/ml): 1) 0.7 + 0.1; 2) 3.8 + 1.2; 3) 1.1 + 0.2; 4) 1.5 + 0.2; 5) 
1.4 + 0.2; 6) 3.5 + 0.5; 7) 3.3 + 0.7; 8) 1.4 + 0.4. The estradiol-treated groups had higher 
P4 than their matched vehicle groups.  
 Two genes in the PVN were significantly correlated with serum hormones. Oxtr 
was positively correlated with serum estradiol concentrations (Figure 1.5A), and Avpr1a 
was negatively correlated with corticosterone (Figure 1.5B). In the SON, Oxtr was 
positively correlated with estradiol and progesterone, and negatively correlated with 
brain-derived neurotrophic factor (Figure 1.5 C, D, E). Detailed statistics for these 
correlations can be found in Supplemental Table S1.2. 
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Figure 1.4: Gene correlations within the PVN and SON 
Correlation are shown between expression of genes. In the PVN, significant positive 
correlations were found for (A) Oxt and Avp, and for (B) Oxtr and Esr2. In the SON, 
positive correlation were found for (C) Oxt and Avp, and for (D) Oxtr and Avpr1a.  
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Figure 1.5: Hormone and gene expression correlations 
Correlations are shown for genes and hormones. In the PVN a significant positive 
correlation was found for Oxtr and serum E2 (A), and a negative correlation for Avpr1a 
and corticosterone (B). In the SON, Oxtr positively correlated with serum E2 (C) and P4 
(E), and negatively correlated with BDNF (D).  
CORT = corticosterone; P4 = Progesterone  
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DISCUSSION 
Since the publication of the results from the WHI, which suggested an increase in 
adverse health outcomes in women taking hormone therapy, the question of whether 
there is a critical window post-menopause during which the body and brain may respond 
positively to hormone replacement has become paramount (Rossouw et al., 2002; 
Anderson et al., 2004). This study utilized a pre-clinical rat model to determine how 
chronological age, and timing and duration of estrogen therapy, affected genes in the 
PVN and SON that, to our knowledge, have not systematically been studied in this 
context. Oxytocin and vasopressin are regulators of social behavior in a variety of animal 
species and humans [reviewed in (Young & Flanagan-Cato, 2012; Winslow et al., 1993; 
Caldwell al., 2008; Ebstein et al., 2012)] so understanding how they change, and estrogen 
regulation, are translationally relevant. 
Our major finding was that it was the receptors for oxytocin and vasopressin, 
rather than the nonapeptides themselves, which were most sensitive to hormones and age. 
The presence and functional importance of these receptors in PVN and SON is far less 
well-studied than that of the peptides themselves, but the literature in general suggests 
that the proteins for these receptors are indeed expressed in PVN and SON of rats (Bealer 
et al., 2006; Ophir et al., 2013), and that there is co-expression of the vasopressin receptor 
1a protein in vasopressinergic neurons in both of these regions (Hurbin et al., 2002). Of 
the nonapeptides oxytocin and vasopressin, the only effect we found was an interaction 
between treatment and duration for Avp in the SON. In rats oxytocin and vasopressin 
affect sexual (Arletti & Bertolini, 1985; Pedersen & Boccia, 2006), aggressive (Bosch & 
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Neumann, 2012; Elkabir et al., 1990) and affiliative (Bosch & Neumann, 2012) 
behaviors, and also influence social interaction and memory (Dantzer et al., 1987; Lukas 
et al., 2011). Therefore, changes in expression of their receptors with age and estradiol 
treatment have potential functional implications and may relate to affective and social 
changes that can occur in some perimenopausal women (Schmidt & Rubinow, 2009).  
 
Gene expression in the PVN – effects of estradiol and age 
The current findings show age and hormone effects on gene expression in a 
region-specific manner. In the PVN, of the five genes measured, only the two-peptide 
receptors, Oxtr and Avpr1a, differed across the groups, each with a unique expression 
pattern. We were surprised not to see effects on of estradiol on Oxt, Avp and Esr2 based 
on the literature on such effects on mRNA and protein in rats (Patisaul et al., 1999; 
Suzuki & Handa, 2004; Akaishi & Sakuma, 1985; Patchev et al., 1995), and age-related 
effects of E2 on vasopressin protein in the human PVN (Ishunina & Swaab, 1999; Fliers 
et al., 1985a). Our lack of age-related changes in Oxt or Esr2 is in line with previous 
research showing no E2 effect on mRNA levels in rats (Wilson et al., 2002; Yamaguchi-
Shima & Yuri, 2007) or protein levels in humans (Ishunina & Swaab, 1999; Wierda et 
al., 1991). Differences are probably attributable to species as well as experimental design 
details, especially the relatively long-term E2 treatments and the specific ages of our 
animals in the current study. 
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Oxytocin receptor in PVN is upregulated by estradiol in 3-month treated MAT and AG 
rats 
 For Oxtr, mature and aging OVX rats given estradiol for 3 months had higher 
expression than their vehicle treated counterparts, when euthanized at ~7 or ~14 months, 
respectively. No differences were found in any of the 6-month treated groups, whether 
given constant hormone or vehicle, or switched after 3 months. There are several 
interpretations of these results, including the fact that the chronological age differences 
between the aging rats at 14 (groups 3 and 4) and 17 months (groups 5-8) may reflect a 
functional transition when Oxtr neurons no longer respond to estradiol. Alternatively or 
in addition, the longer hormone treatment paradigm in the 6-month treatment group (E6), 
the removal of estradiol at the 3-month mark (E3/V3 group), or the delay of estradiol 
treatment for 3 months (V3/E3 group) may represent some adaptation to the longer 
treatment period post-ovariectomy.  
The interactions of estradiol and aging on Oxtr in the PVN have not been widely 
studied, and there are limited studies looking at these factors independently. Young and 
colleagues (1997) reported that short-term (4 day) E2 treatment after given one week after 
ovariectomy did not have a significant effect on Oxtr expression in the PVN. Another 
study found similar results in protein expression of oxytocin receptor in OVX female rats 
given E2 or E2+P starting at the time of OVX and continuing for a 16-day duration 
(Bealer et al., 2006). It is important to note that our treatment duration (3 or 6 months) is 
considerably longer than that of these published studies. Also, the current study 
demonstrated that estradiol treatment was only effective in increasing Oxtr when animals 
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were earlier in the aging process (~14 mo) compared to older (~17 mo) rats. However, 
studies have found that estradiol increases oxytocin receptor protein expression in other 
areas of the hypothalamus such as the supraoptic nucleus, ventromedial nucleus and 
medial preoptic area of rats (Bealer et al., 2006; Tribollet et al., 1990; Patchev et al., 
1993) as well as the medial amygdala and bed nucleus of the stria terminalis (Patchev et 
al., 1993; de Kloet et al., 1986). In a study previously published study utilizing the same 
rats as the current study we found the Oxtr is upregulated by E2 in the medial preoptic 
area (mPOA) (Yin et al., 2015).  
The literature examining Oxtr in the context of aging is even more limited. There 
are no studies, to our knowledge, which have looked at the effects of aging on Oxtr in the 
PVN. However, there is one study that reported age-related increase in Oxtr mRNA in in 
the POA of aging female rats (Mobbs, 1994).  
 
Vasopressin receptor in PVN is upregulated by age in 3-month treated MAT and AG rats 
For Avpr1a expression in the PVN, we found an increase with age in the 3-month 
treated groups, but no further differences in any of the 6-month aging rats, suggesting that 
a plateau may be reached at 14 months of age. One interpretation of this is that the 
amount of Avpr1a is increasing as the animal ages, much as the AVP gene does in the 
human PVN (Ishunina & Swaab, 1999; Fliers et al., 1985a; Swaab et al., 1985). The fact 
that we do not see a response to E2 in both MAT and AG rats could be due to this 
elevated baseline and not necessarily an impaired response to estrogen.  
To our knowledge this is the first study to look at the effects of estradiol and 
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aging on Avpr1a in the PVN, although it was studied during pregnancy in prairie voles 
(Ophir et al., 2013). In other areas of the hypothalamus Avpr1a is influenced by both age 
and/or E2 treatment. In a previous study published by our lab using the same animals as 
the current study we found that E2 down-regulated Avpr1a expression in all groups 
despite age, timing and duration (Yin et al., 2015). This same study also found an 
interaction between age and E2 treatment in the mPOA of MAT and AG 3-month groups 
(Yin et al., 2015). In addition, Kalamatianos and colleagues (2004) found that 4 days of 
estradiol treatment led to an increase in Avpr1a expression in the anteroventral 
periventricular nucleus of female rats. There is one study that has looked at the 
interaction of estradiol and aging in the preoptic area of the hypothalamus. Their results 
revealed that 4 days of E2 injections in young (2 months) and middle-aged (8 months) 
rats led to young estrogen-treated OVX rats having significantly higher Avpr1a mRNA 
than their untreated counterparts, but estrogen treatment did not increase expression in 
the middle-aged rats (Funabashi et al., 2000). However, they did find that the middle-
aged OVX animals had significantly higher Avpr1a expression than young OVX rats 
(Funabashi et al., 2000).  
 
Gene expression in the SON – effects of estradiol and age 
In the SON, three out of the four genes measured, Avp, Oxtr and Avpr1a, but not 
Oxt, differed across the groups. The literature on whether or not estradiol has an effect on 
Oxt in the SON is mixed, with some finding an increase or decrease, as reported for 
mRNA levels in rats (Peter et al., 1990; Van Tol et al., 1988), and others finding no 
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effects on protein levels in rats (Shughrue et al., 2002; Rhodes et al., 1981) and mice 
(Alves et al., 1998). One possible explanation for why we see changes in Avp but not in 
Oxt with E2 treatment is that co-expression of ERβ protein and mRNA is higher in 
vasopressin than oxytocin neurons of rats (Shughrue et al., 2002; Isgor et al., 2003) and 
mice (Alves et al., 1998). Double-labeling studies would be needed to test this hypothesis 
in our model.  
In addition, Oxt expression was not affected by age, which in part is supported by 
past studies. In post-menopausal women oxytocin neuronal volume and cell numbers are 
not altered by age (Wierda et al., 1991; Ishunina & Swaab, 1999; Hoogendijk et al., 
1985), which is in line with the current study, and suggesting that there is not higher 
activity of oxytocin neurons when steroid hormones are lost or replaced. However, we 
were surprised that age did not affect Avp, due to the findings in humans of an increased 
somatic size of vasopressin neurons, as well as increased numbers of these neurons in the 
SON, although these studies did not taken into account hormone replacement therapy 
(Ishunina & Swaab, 1999; Fliers et al., 1985a; Hoogendijk et al., 1985). Yet, we did see 
age-related changes in both Oxtr and Avpr1a expression. It is possible that this is due to 
species differences, with age playing a larger role in regulating the receptors in rodents 
and the genes themselves in humans.  
 
Oxytocin receptor in SON is regulated by age in 3-month treated MAT and AG rats and 
by timing of estradiol treatment in AG rats.  
Oxtr expression in the SON was affected by age, with mature animals having 
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significantly less than their aged counterparts. In addition, the aged animals that had 
delayed estradiol treatment had significantly more Oxtr than the aged animals with 6 
months of vehicle treatment and those who were deprived of treatment for 3 months prior 
to euthanasia. This demonstrates that even after being deprived of steroid hormones for 3 
months, estradiol replacement is still effective in increasing Oxtr. The delayed treatment 
brought the aged animals back to the level similar to those who were euthanized at ~14 
months. This is an indication that there is not a critical window for the effectiveness of 
estradiol on regulation of this gene in the SON.  
The few studies published on the effects of estradiol on oxytocin receptor in the 
SON have reported mixed results. Young and colleagues (1997) found that there were no 
changes of Oxtr in the SON of rats during the different stages of the estrous cycle or 
during pregnancy. Yet, a study looking at the effects of E2 and E2+P treatment after OVX 
in female rats found that both treatments increased protein expression of oxytocin 
receptor in the SON compared to the control group (Bealer et al., 2006). The same study 
also showed that levels of the oxytocin receptor are increased during late gestation 
compared to early gestation and OVX control animals (Bealer et al., 2006). Similar 
results have been seen in pregnant prairie voles, with Oxtr being unregulated during late 
pregnancy, a time when steroid hormones such as estradiol are high (Ophir et al., 2013). 
Our results support the latter findings that estradiol does indeed play a role in the 
regulation of Oxtr in the SON. In regard to aging, Oxtr in the SON has not been studied. 
However, findings from other nuclei do indicate that aging does play a role in regulating 
oxytocin receptor mRNA and protein expression in the hypothalamus of the rat (Mobbs, 
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1994; Arsenijevic et al., 1995).  
 
Vasopressin receptor in SON is regulated by age in 3-month treated MAT and AG rats. 
 In addition to seeing age effects of Avpr1a in the PVN we also saw age-related 
changes in the SON. We found an increase with age in the 3-month treated groups, but no 
differences in any of the 6-month aging rats. As previously mentioned, this could be due 
to species difference, with age affecting Avpr1a expression in rats and Avp in humans. To 
our knowledge, this is the first study to examine the effects of age and estradiol on 
Avpr1a expression in the SON. Previous studies indicate both age and estradiol treatment 
affects other parts of the hypothalamus (Kalamatianos et al., 2004; Funabashi et al., 
2000).  
 
Vasopressin in SON is down regulated by estradiol in 6-month treated AG rats. 
 The SON was the only region in which Avp changed, decreased by E2 in the 6-
month treatment group. As the SON ages from 14 to 17 months the responsiveness to E2 
treatment appears to change. Literature on the effects of estradiol on Avp is mixed, with 
some showing no effects and other showing increases. E2 did not alter vasopressin protein 
or gene expression in the SON of mice (Nomura et al., 2002); nor did it have an effect on 
mRNA in the monkey (Roy et al., 1999). However, a study looking at the effects of E2 
post OVX in female mice found that 3 days of consecutive E2 treatment led to an increase 
in vasopressin protein in the SON (Grassi et al., 2010). E2 has also been shown to 
increase expression of Avp in the bed nucleus of the stria terminalis of rats (Han & De 
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Vries, 2003), and decrease mRNA and protein in the medial amygdala and lateral septum 
of mice (Nomura et al., 2002).  
 Again, we were surprised to not see any age effects in Avp expression. As stated 
previously this may be due to species differences, because previous changes in 
expression have been found in humans but not rodents. In addition, the findings in 
humans of an increased somatic size of vasopressin neurons, as well as increased 
numbers of these neurons did not take into account hormone replacement therapy 
(Ishunina & Swaab, 1999; Fliers et al., 1985a).  The decrease in Avp in our aged rats but 
not our mature rats could be an indication that long-term estradiol treatment reverses the 
protective effects that accompany normal aging.  
 
Correlation results and new hypotheses 
We conducted the gene and hormone correlations as a way to generate future 
hypothesis based on the relationships among genes, and between genes and hormones. 
The Avp and Oxt genes were positively correlated with each other in both brain regions. 
More surprising was the significant positive correlation between Avpr1a and Oxtr in the 
SON; while relatively weak, it poses the possibility that these receptors are co-regulated 
by age and hormones. In fact, both Avpr1a and Oxtr were upregulated by age in the SON, 
consistent with this hypothesis. Correlations conducted between genes and hormones also 
identified positive and negative relationships. For example, there was a significant 
negative correlation between corticosterone and Avpr1a. There are studies showing that 
stress can increase corticosterone levels and Avp expression in the parvocellular neurons 
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in the PVN (Pinnock & Herbert, 2001; Ma et al., 1997; Makino et al., 1995), but 
relationships between corticosterone and Avpr1a are not as well known and merit future 
research. Serum E2 correlated positively with Oxtr in both brain regions and suggests that 
the oxytocin receptor is an important target for menopause research. 
 
CONCLUSIONS, CLINICAL IMPLICATIONS, AND LIMITATIONS  
The current study is the first to look at the affects of age, and timing and duration 
of estradiol on social behavior related genes in the PVN and SON of female rats. Results 
on Avpr1a and Oxtr show that most differences occurred in animals with shorter 
treatment durations and of younger chronological ages. There were exceptions though, as 
Avp and Oxtr in the SON showed some unexpected duration (Avp) and timing (Oxtr) 
effects. Estradiol’s ability to increase Oxtr even after the animal has been deprived of 
steroid hormones for 3-months and that timing did not affect any other genes is an 
indication that the “critical window” hypothesis is supported for specific genes (Avpr1a 
and Oxtr) but not others.  
These findings could also have clinical implications for women taking hormone 
replacement therapy. Both Oxt and Avp have been implicated in regulating a variety of 
behaviors such as anxiety and depression, in mice (de Kloet et al., 2005), rats (Klenerova 
et al., 2009), humans (Meyer-Lindenberg et al., 2011), and voles (Lim and Young, 2006). 
Oxtr and Avpr1a knockout mice show aberrant social and emotional behaviors, including 
increasesd aggression, stress and deficits in social memory (Bielsky et al., 2004; Sala et 
al., 2011; Takayanagi et al., 2005). The decrease of Oxtr that is experienced when 
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estradiol levels drop may contribute to these behavioral changes. However, whereas 
shorter-term treatment with E2 causes an increase in expression of some genes, long-term 
treatment did not have any effects on any of the genes except Avp, which was down-
regulated. According to the “critical window” hypothesis there is a point in which 
hormone replacement therapy because more detrimental than it is helpful. This decrease 
in expression of Avp may be indicative of such a negative effects of long-term treatment.  
There were several limitations to the current study. We were not able to include a 
delayed treatment group in our MAT animals due to the fact that they would have been 
entering reproductive senescence, which would have introduced a confound to our study. 
There were also technical pitfalls: we were only able to obtain enough RNA to assay 5 
genes in PVN and 4 in SON. In addition, while the study was adequately powered to 
detect significant group differences, sample sizes for some of the genes were small. It is 
also notable that there is quite a bit of individual variability of gene expression within 
groups. This is not surprising considering the complex experimental model and the 
inevitable differences between outbred rats of strains such as Sprague-Dawley. This may 
be an advantage though from a clinical perspective, as humans are not inbred and 
symptoms and other characteristics of menopause vary enormously from woman to 
woman. 
There are several areas that merit future investigation to enhance the clinical 
relevance of the work. Here, we only tested continuous E2 and we did not replace 
progesterone, though women with a uterus may use cyclic regimes of hormones that 
include P4. Including P4 treatments in our study would have doubled the number of 
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animals needed, thus we decided to focus on addressing and reevaluating the limitations 
of the WHI estrogen-alone trials. Currently, we are determining direct relationships 
between the timing and duration of E2 treatment on neurobehavioral outcomes of animals 
that are behaviorally characterized. This will give us a better understanding of links 
between gene regulation and behavior, to inform treatment options for menopausal 
women.  
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SUPPLEMENTAL TABLES 
 
Table S1.1 Oxt 
(PVN) 
Avp 
(PVN) 
Oxtr 
(PVN) 
Avpr1a 
(PVN) 
Esr2 
(PVN) 
Oxt 
(SON) 
Avp 
(SON) 
Oxtr 
(SON) 
Avpr1a 
(SON) 
Oxt (PVN) ------- 0.001* 0.380 0.389 0.128 0.552 0.360 0.552 0.858 
Avp (PVN)  ------- 0.320 0.073 0.088 0.255 0.268 0.255 0.808 
Oxtr (PVN)   ------- 0.189 0.001* 0.823 0.433 0.823 0.272 
Avpr1a 
(PVN) 
   ------- 0.140 0.706 0.319 0.706 0.207 
Esr2 (PVN)     ------- 0.210 0.114 0.210 0.959 
Oxt (SON)      ------- 0.001* 0.454 0.150 
Avp (SON)       ------- 0.146 0.074 
Oxtr (SON)        ------- 0.003* 
Avpr1a 
(SON) 
        ------- 
 
Table S1.1: Significant gene correlations 
P-values are shown for the gene correlations, all of which were positive. In the PVN, 
significant correlations were found for Oxt and Avp, and for Oxtr and Esr2. In the SON, 
correlations were found for Oxt and Avp, and for Oxtr and Avpr1a. All significant p 
values are indicated with an asterisk. 
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Table S1.2 Avp 
(PVN) 
Oxt 
(PVN) 
Avpr1a 
(PVN) 
Oxtr 
(PVN) 
Esr2 
(PVN) 
Avp 
(SON) 
Oxt 
(SON) 
Avpr1a 
(SON) 
Oxtr 
(SON) 
E2 0.501 0.582 0.321 0.039* 0.532 0.203 0.609 0.958 0.013* 
BDNF 0.496 0.985 0.299 0.651 0.145 0.481 0.994 0.186 0.029* 
CORT 0.112 0.679 0.031* 0.287 0.685 0.195 0.227 0.918 0.675 
P4 0.911 0.549 0.282 0.541 0.953 0.277 0.978 0.992 0.003* 
 
Table S1.2: P-values for correlations between the hormone assays and the target genes in 
both the PVN and SON. 
 
In the PVN, a significant negative correlation was found for Avpr1a and corticosterone, 
and a positive correlation for Oxtr and serum E2. In the SON, Oxtr correlated positively 
with serum E2 and P4, and negatively with BDNF. All significant p values are indicated 
with an asterisk. 
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CHAPTER 3: THE EFFECTS OF LONG-TERM ESTRADIOL 
TREATMENT ON SOCIAL BEHAVIOR AND GENE EXPRESSION 
IN MATURE ADULT FEMALE RATS. 
 
ABSTRACT 
This study tested the effects of long-term estradiol (E2) replacement on social 
behavior and gene expression in ovariectomized mature adult female rats. We used an 
ultrasonic vocalization (USV) test and a sociability test to examine communication, and 
social memory and preference, in the social context of female-female cagemates. 
Underlying neurobiological molecular changes were quantified in 5 brain regions 
involved in social behavior using a 48-gene qPCR array. In the USV test, E2 profoundly 
decreased numbers of USVs and decreased interactions scored from videotapes. There 
were few effects of E2 in the sociability test. For gene expression, the supraoptic nucleus 
(SON) was most affected: Oxt, Oxtr and Avp were increased in E2 rats, and Drd2, Htr1a, 
Grin2b, and Gabbr1 were decreased. Thus, E2 changes communicative interactions 
between adult female rats, and genes involved in oxytocin, vasopressin, and 
neurotransmitter signaling in the SON were selectively affected.  
 
INTRODUCTION   
The loss of ovarian estrogens during natural or surgical menopause results in a 
variety of symptoms that can impair the quality of life. Among the neurological and 
neurobehavioral symptoms reported by perimenopausal women are increased depression 
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and anxiety (Freeman et al., 2004; Schmidt et al., 2004; Bromberger et al., 2011). 
Estrogens, especially estradiol (E2), regulate these behaviors in animals as well as 
women (de Kloet et al., 2005; Klenerova et al., 2009; Meyer-Lindenberg et al., 2011; 
Rubinow et al., 1998). Clinical studies have shown that women given estradiol have 
decreased anxiety and depression symptoms compared to women given placebo (De 
Novaes Soares et al., 2001; Zweifel & O’Brien, 1997, Schmidt et al., 2000). However, 
there is controversy about the risks and benefits of hormone replacement therapy (HRT) 
following the publication of the results from the Women’s Health Initiative, which 
suggested a small but significant increase in adverse cardiovascular and breast cancer 
incidents in women taking HRT (Rossouw et al., 2002; Manson et al., 2013). Although 
those findings have been partially discredited (Klaiber et al., 2005; Bhupathiraju and 
Manson, 2014), to this day the question of whether, when, and for how long HRT should 
be used is still debated. 
Along with its effects on affective behavior are estradiol’s effects on social 
behavior. In rodents, ovariectomy causes deficits in social interaction and social memory 
that are improved with administration of estradiol replacement (Hlinák, 1993; Tang et al., 
2005). Mice with knockouts for the estrogen receptor α (ERα) or ERβ genes also exhibit 
social behavioral deficits (Choleris et al., 2006; Imwalle, Scorkakales & Rissman, 2002). 
This appears to translate to humans, as women with menopausal depression or anxiety 
report problems with interpersonal relationships and a decreased desire to engage in 
social interactions (Uguz et al., 2011; Deeks and McCabe, 2004; Lanza di Scalea et al., 
2012; Schmidt et al., 2000). Schmidt and colleagues (2000 & 2015) have reported that 
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estradiol decreased social isolation during perimenopause compared to placebo, whereas 
another study found that hormone replacement therapy was associated with an increase in 
social isolation (Achat et al., 1998). Therefore, the effect of HRT on social behavior 
requires further investigation.  
The neurobiology of social behavior involves a complex network of brain regions 
that signal via diverse cellular and molecular pathways. The prefrontal cortex (PFC), 
medial amygdala (MeA), bed nucleus of the stria terminalis (BNST) and the 
hypothalamus are among the most estrogen-sensitive nodes of this neural circuit 
(Arimatsu & Hatanaka, 1986; Kugaya et al., 2003; Han & De Vries, 2003; Garcia et al., 
2016). Considering their key roles and abundant expression of ERs (Kugaya et al., 2003; 
Walker et al., 2003; Saper et al., 2005), they are important targets of analysis for 
understanding potential neuromolecular substrates involved in the estrogen-regulation of 
social behavior. 
This study was designed in order to gain insight into how long-term estradiol 
treatment affects social memory and social interaction in female rats, using novel 
behavioral tasks designed to assess sociality in cagemates. In addition, to gain insight into 
the molecular changes that occur with estradiol deprivation and replacement, we 
systematically profiled the expression of genes that are implicated in the regulation of 
social behavior, and that are estrogen-sensitive.  
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MATERIAL AND METHODS 
Animals and Husbandry 
Animal procedures were conducted in accordance with The Guide for the Care 
and Use of Experimental Animals following protocols approved by The University of 
Austin IACUC committee and NIH standards. Reproductively mature adult female 
(MAT, 3-4 months, sexually naïve, n = 40) Sprague Dawley rats (Harlan) were 
purchased. Upon arrival, rats were placed on a standard 12:12 light: dark cycle (lights on 
at 0700) and paired housed, and given water and rat chow ad libitum. Prior to surgery 
they were allowed to acclimate to the room for two weeks. During this period estrous 
cyclicity was monitored daily by vaginal lavage of sterile saline. Only females with 
regular 4-5 day cycles were used. Ovariectomy (OVX) surgery was performed on all rats 
under isofluorane inhalation anesthesia. A single injection of Rimadyl (5 mg/kg) was 
given at the start of surgery. Bilateral dorsolateral incisions were made through the skin, 
muscle, and peritoneum, and the ovaries were ligated and removed. Muscles were sutured 
and wound clips used to close the skin. At the time of surgery animals were implanted 
subcutaneously between the shoulder blades with capsules containing either 100% 
cholesterol (Veh) or 5% 17β-estradiol / 95% cholesterol (E2). Animals were randomly 
assigned to treatment groups, and pair-housed with a rat that received the same treatment 
for 3 months. The final number of experimental rats was n = 20 (Veh) and n= 20 (E2).  
 
Behavioral paradigms 
 Behavioral testing began 3 months after OVX and hormone treatment, when rats 
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were ~7 months of age. At that time, all animals were separated from their cagemates for 
one week and individually housed. Testing began with an ultrasonic vocalization test (2 
consecutive days) followed the next day by sociability testing (2 consecutive days). Rats 
were euthanized one week after the completion of testing. 
 
Ultrasonic vocalization test (USV)  
USV testing took place over 2 consecutive days in a Plexiglas tank (23L x 29W x 
40H cm, Fig. 2.1a) placed inside of a sound-attenuating chamber equipped with a 
microphone. On Day 1, animals were allowed to habituate (Trial 1) for 5 minutes, during 
which USVs were recorded on the individuals. Day 2 consisted of a sequence of three 5-
minute trials, referred to as Trials 2, 3, and 4, in which the cagemates were re-introduced, 
allowed to interact, and subsequently separated. In Trial 2 prior to placement of the rats, a 
removable perforated plastic grid was placed across the center of the apparatus to bisect 
it; it allowed for nose touching, auditory and visual contact but not gross physical contact. 
The cagemates were re-introduced during this trial but were separated by the grid. USVs 
were recorded from the pair. For Trial 3, the grid was removed and the rats were able to 
freely interact with one another. Videotaping was performed during this trial in order to 
quantify activity, time interacting, and anogenital investigation. Before the start of Trial 4 
one of the cagemates was (randomly) removed from the testing chamber and placed into 
an identical chamber in a separate sound-attenuated chamber. Both animals were then 
immediately recorded for a final 5-minute trial before being individually rehoused.  
 USVs were recorded using UltraSoundGate hardware and software and analyzed 
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with Saslab Pro (all Avisoft, Germany). We were able to use the Saslab Pro software to 
automatically detect and quantify calls, between 45 and 70kHz, and to differentiate them 
as frequency modulated (FM) or non-frequency modulated (NFM). Frequency modulated 
calls were defined as having more than a 9kHz change in frequency. Each pair of 
cagemates was analyzed as a unit, because during tests when both animals were present 
in the same chamber, it was impossible to distinguish calls from individuals. Therefore, 
for Trials 1 and 4, when the animals were recorded separately, their calls were summed 
for statistical analysis.  
 During Trial 3, while rats were allowed to physically interact, the behavioral test 
was recorded using a digital videocamera. Recordings were subsequently analyzed by a 
blind observer for overall activity, interaction and anogenital investigation. 
Statistical analyses were conducted using SPSS. Due to the non-homogeneity of 
these data sets all data were transformed using either a square root or log transformation. 
One pair of animals from the vehicle treated group was removed as an outlier, due to 
calls being more than 2 SD above the mean of the group. The final number of pairs used 
for USV analysis was 9 and 10 for E2 vs. Veh, respectively. A repeated measures test was 
used to analyze the effects of treatment (E2 vs. Veh) and trial (Trials 1 through 4) for total 
calls, non-frequency modulated calls, and frequency-modulated calls. For all of these 
analyses, alpha was set at 0.05 and significant main or interaction effects were followed 
by two-tailed independent sample t-tests. Independent sample t-test was also used to 
analyze the difference between treatments on overall activity, interaction and anogenital 
investigation. Correlations between USV behavior and calls made during trial 2, while 
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the animals were freely interacting, were analyzed using a Spearman’s rank correlation.  
 
Sociability test  
 On day 1 one of the cagemates was randomly chosen to be the experimental rat 
and was habituated to a Stoelting three-chamber apparatus (100L x 100W x 34.5H cm 
total) containing two holding cages in each corner of the side chambers, for 5 minutes 
prior to testing. After the habituation trial the experimental animal was placed back in its 
home cage, during which time its cagemate was placed in one of the two holding cages 
[small cage in one of the far corners (lower-left and lower-right, Fig 2.1b)]. Holding 
cages have bars that allow for nose touching and anogenital investigation between the 
bars. The second holding cages was used to house a novel (unfamiliar) rat of the same 
sex, age, and treatment. The experimental rat was then placed back into the center 
chamber and was allowed to roam freely for a 5-minute sociability test, during which her 
behaviors were tracked by Any-Maze software (Stoelting Co., Wood Dale, IL). Rats were 
re-housed separately overnight. On day 2 the cagemate that was previously used as a 
stimulus rat was used as the experimental rat. That rat’s partner was now placed into a 
holding cage, and the other holding cage contained a new unfamiliar rat of the same sex, 
age, and treatment. Again, the experimental rat’s movements were tracked by Any-Maze. 
The software was subsequently used to quantify time immobile, time spent in each 
chamber, and time spent in a smaller 19 x 19 cm zone (approximately one body length 
distance) designated around the stimulus rats (Fig 2.1b). After the end of day 2 of 
sociability testing animals were rehoused with their cagemate for one week until time of 
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euthanasia.  
 Statistics were conducted using SPSS. Due to the violation of assumptions total 
time freezing and time spent near stimulus rat were transformed using a log and square 
root transformation, respectively. Data for time immobilized near stimulus rat, time spent 
in chambers, and time immobilized in chambers did not meet assumptions even after 
transformation. Therefore, a Friedman’s test was performed to analyze the effect of 
chambers while Wilcoxon signed-rant test was performed to analyze the effect of 
treatment. A false discovery rate correction was used to correct for the multiple 
comparisons.  
  
 62 
 
Figure 2.1a: Ultrasonic vocalization apparatus 
 
The ultrasonic vocalization apparatus and set-up are shown for Trials 2 and 3. A) In Trial 
2 the cagemates were reintroduced across a perforated plastic grid that allowed sniffing 
and nose-touching but no other physical interactions. USVs were recorded for 5 minutes. 
B) In Trial 3 the grid was removed from the apparatus and the cagemates were allowed to 
freely interact, and USVs recorded for 5 minutes. Trial 3 was also videotaped and scored 
for activity, time interacting, and time engaged in anogenital investigation. During Trials 
1 and 4 the animals were alone in the apparati and recorded separately (image not 
shown). 
 
 
 
 
 
 
 
 
 
 
Figure 2.1a
A. B.
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Figure 2.1b: 3-chamber sociability test apparatus 
 
The 3-chamber sociability test apparatus is shown, with a representative behavioral path 
of an individual experimental rat shown as tracked by ANY-maze. The black square 
around each of the two corner holding cages represents the area in proximity to the 
stimulus rats. For the sociability test the experimental rat’s cagemate (CM) was placed in 
one of the two corner holding cages while a novel (N) rat of the same age, sex and 
treatment was placed in the other. The experimental rat was placed in the center chamber 
and allowed to explore the apparatus for 5 minutes.  
  
Sociability Test
CM         N
Figure 2.1b
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Brain tissue processing 
 Rats were euthanized at ~7 months of age. All animals were weighed and 
euthanized during the lights-on period at 1330 hours, with the last animal killed not later 
than 1600 hours, by rapid decapitation. After brains were removed they were sectioned 
using an ice-cold stainless steel brain matrix, 1-mm coronal sections were taken. 
Cryogenic storage vials that contained RNAlater (Life technologies, Grand Island, NY) 
were used to store sections overnight at 4°C. Sections were then mounted onto chilled 
slides and placed in a -80°C freezer until brain punches were taken. Bilateral punches of 
brain tissue were taken using Palkovits punches and the Paxinos and Watson (2009) rat 
brain atlas (all coordinates are based on that atlas) under a dissecting microscope. The 
paraventricular nucleus of the hypothalamus (PVN) punch (1.22 mm diameter) began 
rostrally at ~Bregma = -0.84 mm, and extended caudally 1 mm. The supraoptic nucleus 
(SON) punches (0.96 mm diameter) started rostrally at ~Bregma = -0.60 mm and 
extended caudally for 1 mm. MeA punches (1.22 mm diameter) began rostrally at 
~Bregma = -1.56 mm, and extended causdally 1mm.  BNST punches (0.96 mm diameter) 
started rostrally at ~Bregma = 0.00 mm, and extend caudally for 1mm. PFC punches 
(1.22 mm diameter) began rostrally at ~Bregma = 4.20 mm, and extend caudally for 
1mm. Punched tissue was placed in a frozen Eppendorf tube and stored at -80°C until 
time of PCR. At decapitation, trunk blood was collected, allowed to clot, centrifuged 
(2300 X g for 5 minutes), and serum collected. Serum was stored at -80°C in Eppendorf 
tubes until time of hormone assays.  
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Real-time PCR assays and analysis 
 Extraction of RNA from frozen PVN, SON, MeA, BNST, and PFC punches was 
performed using an Allprep RNeasy mini kit (Qiagen, Valencia, California), according to 
the manufacturer’s protocol. The quality of the RNA was validated using an Agilent 2100 
Bioanalyzer (Agilent, Santa Clara, CA) and all RIN values fell in the range of 8.80 to 
9.90. A GloMax-Multi Detection System (Promega, Madison, WI) was used to assess the 
quantity of RNA. After RNA extraction mRNA (200ng) was converted to single-stranded 
cDNA using a high-capacity cDNA reverse transcription kit (Life Technologies, Grand 
Island, NY), samples then stored at -20°C until use. Samples from all 5-brain regions (n = 
11 - 18 per group) were run on a customized rat Taqman low-density array (TLDA) 
Microfluidic 48-gene real-time PCR cards (Applied Bio- systems).  Real-time PCR was 
performed using Taqman universal mastermix (Life Technologies, Grand Island, NY) 
and detected on a ViiA7 Real time PCR machine (Applied Biosystems, Life 
Technologies, Grand Island, NY) with the following run parameters: 0°C for 2 minutes, 
95°C for 10 minutes, 45 cycles of 95°C for 15 seconds, and 60°C for 1 minute. 
The genes for the assay were chosen based on their roles in social behavior and their 
regulation by steroid hormones (45 genes of interest and three normalizing genes; Table 
1).  
Relative expression was determined for each sample using the comparative cycle 
threshold method (Pfaffl, 2001; Schmittgen & Livak, 2008). All samples were 
normalized to the geomean of the housekeeping genes Gapdh, Rpl13a, and 18s and then 
calibrated to the median δ-cycle threshold of the vehicle treated group. Samples that 
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amplified at or above 35ct were excluded from analysis and any samples 2 SD above the 
mean of the group were removed as outliers.   
 The effect of treatment (E2 vs. Veh) on TLDA gene expression was analyzed 
using independent sample t-test using SPSS. Those data that did not pass the assumptions 
of normality and/or variance were transformed using either a square root or log 
transformation. Data that did not meet assumptions even after transformation were 
analyzed using a Kruskal-Wallis test. For all of these analyses, alpha was set at 0.05 and 
the Benjamini-Hochberg false discovery rate correction method (FDR; Benjamini & 
Hochberg, 1995) was used to correct for the multiple comparisons.  
 
Estradiol hormone assay 
 Levels of serum estradiol (E2) were determined by radioimmunoassay 
(Ultrasensitive Estradiol RIA, Cat No DSL4800, Lot # 150622C, Beckman Coulter, 
Pasadena, CA), according to the manufacturer’s directions. A single assay was used for 
all the samples. Samples were run in duplicates with volumes of 100 µl of serum. Assay 
sensitivity was 2.2 pg/ml and intrassay C.V. was 1.30%. As expected, the estradiol 
treated animals had significantly higher concentrations of E2 (37 + 3) than did the vehicle 
(14 + 1) treated animals (p < 0.01).   
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RESULTS 
Ultrasonic vocalizations  
USV calls 
 Analysis of total calls showed a significant interaction between trial and treatment 
(p < 0.05). Vehicle treated animals called significantly more than E2 treated animals on 
Trials 2 (p < 0.05) and 3 (p < 0.01) (Fig 2.3A). When differentiated into frequency 
modulated (FM) and non-frequency modulated (NFM) calls, analysis of FM calls yielded 
a significant main effect of trial (p < 0.01), with more calls being emitted by both 
treatments on Trial 3 than Trials 1 and 4 (p < 0.01, Fig 2.3B). For NFM calls, a 
significant interaction between trial and treatment was found (p < 0.05) with the vehicle 
rats emitting significantly more NFM calls on Trial 3 (p < 0.01, Fig 2.3C) than the E2 
treated animals.  
 
Behavior during USV Trial 3 
 Videorecordings were scored for overall activity, interaction and anogenital 
investigation. Independent-sample t-tests showed that there was a significant difference 
between the treatments on all 3 behaviors (p < 0.01). The vehicle rats were significantly 
more active (Fig 2.4A) during the test and they spent more time interacting (Fig 2.4C) 
with their cagemate than did the E2 animals. However, E2 treated animals participated in 
significantly more anogenital investigation with their cagemate than did the vehicle 
treated animals (Fig 2.4E).  
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Correlations between total USVs and behaviors in Trial 3 
 Correlations were performed to examine the relationship between total calls 
emitted during Trial 3 and the behaviors scored during that trial. Total calls were 
positively correlated with activity (p < 0.01, Fig 2.4B) and time interacting (p < 0.01, Fig 
2.4D). However, anogenital investigation was negatively correlated with total calls (p < 
0.01, Fig 2.4F). 
 
Sociability test  
 Vehicle treated animals spent significantly more time immobile during the 
sociability trail than E2 treated animals (p < 0.05, Fig 2.5A). The E2 animals also spent 
more time immobile in close proximity to their cagemate than they did with the novel rat 
(p < 0.01, Fig 2.5B). The vehicle treated animals spent more time immobile in proximity 
to the novel rat than did the E2 treated animals (p < 0.05, Fig 2.5B) Rats in both 
treatments spent more time in proximity to their cagemate than the novel rat (p < 0.05, 
Fig 2.5C). The vehicle treated animals on average had longer visits to their cagemate than 
they did with the novel rat (p < 0.05, Fig 2.5D). 
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Figure 2.3: Numbers of USV calls 
 
Note that the y-axis varies across graphs. A) The total number of USVs was significantly 
higher in Veh than E2 treated animals on Trials 2 and 3. B) Non-frequency modulated 
(NFM) calls were high in Veh than E2 rats on Trial 3. C) For FM calls both veh and E2 
called significantly more on Trial 3 compared to all other trials, and more FM calls on 
Trial 2 than on Trial 1. However, there were no significant treatment effects for FM 
USVs. Data are shown + SEM. Significant differences are shown as single asterisk for p 
values less than 0.05 (* = p < 0.05) and double asterisk for p values less than 0.01 (** = p 
< 0.01). 
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Figure 2.4: USV behavior and correlations 
 
Behavior data are shown from videotapes taken during Trial 3 of the USV test. Note that 
the y-axis varies across graphs. A) Activity, measured by the number of line crosses, and 
C) time interacting, were significantly lower in E2 compared to Veh rats. E) By contrast, 
time spend participating in anogenital investigation was significantly higher in the E2 
rats. Correlation analyses were performed for these 3 measures and the total number of 
USVs measured in Trial 3. B) Activity and D) time interacting were positively correlated 
with total USVs, whereas F) time spent enaged in anogenital investigation was negatively 
correlated with total USVs. A-C: Data are shown + SEM. Significant differences are 
shown as double asterisk for p values less than 0.01 (** = p < 0.01). 
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Figure 2.5: Sociability behavior data  
 
Note that the axes vary across graphs. A) Total time spent immobile was significantly 
greater in Veh than E2 rats. B) When this behavior was further analyzed in proximity to 
the cagemate or novel stimulus rat, the E2 group spent more time immobilize near the 
familiar (cagemate) rat than the novel rat. There was also a treatment effect seen for time 
spent immobile near the novel stimulus rat, with Veh rats significantly greater than the 
E2 animals. C) More total time was spent near the cagemate than the novel rat, for both 
treatment groups. D) Veh animals had on average longer visits to the cagemate. Data are 
shown + SEM. 
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Gene expression  
All gene expression results are summarized for PVN, BNST, MeA, SON, and PFC in 
Table 2.1 Statistics are reported only for genes surviving the false discovery rate test. 
 
Paraventricular nucleus 
 Only one gene, progesterone receptor (Pgr) was significantly affected treatment 
in the PVN, which was upregulated by E2 compared to Veh (p < 0.01, Fig 2.6A).  
 
Bed nucleus of the stria terminalis 
 Three genes showed a significant effect of treatment in the BNST. Oxytocin 
receptor (Oxtr) was upregulated by E2 (p < 0.01, Fig 2.6B) while estrogen receptor beta 
(Esr2) and DNA methyltransferase 3 alpha (Dnmt3a) were downregulated by E2 (p < 
0.01, Fig 2.6C & p < .0.05, Fig 2.6D, respectively).  
 
Medial amygdala 
 In the MeA there were three genes that were significantly upregulated by E2: Oxtr 
(p < 0.01, Fig 2.6E), androgen receptor [(Ar) p < 0.05, Fig 2.6F] and forkhead box P1 
[(Foxp1) p < 0.01, Fig 2.6G].  Tachykinin 3 (Tac3) was downregulated by E2 in the MeA 
(p < 0.01, Fig 2.6H).  
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Supraoptic Nucleus 
 A total of 10 genes were significantly altered by E2 treatment. Of these, 3 were 
upregulated by E2 in the SON, all related to social behavior (Fig 2.7A-C): oxytocin [(Oxt) 
p < 0.01], Oxtr (p < 0.05), and vasopressin [(Avp) p < 0.05]. Seven genes were 
significantly down-regulated by E2 in the SON (Fig 2.7C–J), mainly involved in 
neurotransmission and epigenetic regulation: dopamine receptor D2 [(Drd2) p < 0.05], 
serotonin receptor 1A [(Htr1a) p < 0.01], forkhead box P2 [(Foxp2) p < 0.05], histone 
deacetylase 2 [(Hdac2) p < 0.01], histone deacetylase 4 [(Hdac4) p < 0.01], glutamate 
receptor 2b [(Grin2b) p < 0.05], and GABA-B receptor 1 [(Gabbr1) p < 0.05]. 
 
Prefrontal cortex 
 Although two genes were upregulated by E2 in the PFC, dopamine receptor D2 
(Drd2) and Oxtr, they did not survive false discovery rate correction for multiple 
comparisons.  
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Figure 2.6: Relative gene expression data for the PVN, BNST and MeA 
 
Note that the scale of the y-axis varies depending on the gene. A) In the PVN, Pgr was 
significantly higher in E2 than Veh rats. B-D) In the BNST, Oxtr was increased, and Esr2 
and Enmt3a decreased, by E2 compared to Veh.  E-H) In the MeA, Oxtr, Ar and Foxp1 
were increased, and Tac3 decreased, by E2 compared to Veh. Data are shown + SEM. 
Significant differences are shown as single asterisk for p values less than 0.05 (* = p < 
0.05) and double asterisk for p values less than 0.01 (** = p < 0.01). 
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Figure 2.7: Relative gene expression data for the SON  
 
Note that the scale of the y-axis varies depending on the gene. A-C) Oxt, Oxtr, and Avp 
were higher in estradiol than vehicle treated animals. D-J) Drd1, Htr1a, Foxp2, Hdac2, 
Hdac4, Grin2b, and Gabbr1 were lower in E2 than Veh treated animals. Data are shown 
+ SEM. Significant differences are shown as single asterisk for p values less than 0.05 (* 
= p < 0.05) and double asterisk for p values less than 0.01 (** = p < 0.01). 
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DISCUSSION 
This study assessed effects of estradiol on social behavior, and on the underlying 
neuromolecular circuits involved in the regulation of these behaviors. We designed and 
utilized novel tests of USV communications and social novelty and preference between 
same-sex cagemates to assess the influence of E2 on these interactions. This experimental 
model, focusing on social interaction and social preference between adult female rats, and 
USVs emitted in the context of familiar non-intruder female-to-female interactions, 
differs from the literature that typically focuses on opposite-sex interactions (Matochik et 
al., 1992b; Bialy et al., 2000; Harding & McGinnis, 2003). 
Our results showed that 3 months of E2 replacement to OVX rats, roughly 
estimated as ~5 years in humans (Sengupta, 2013; Quinn, 2005) substantially changed 
these behaviors in several surprising ways. In the USV test, compared to E2 rats, vehicle 
rats engaged in USV calling at significantly higher levels, had greater activity and time 
interacting, but much lower anogenital investigation. In the sociability test, the expected 
preference of a rat for a novel compared to a familiar conspecific was not seen in the 
context of our cagemate model, where rats of both treatments spent more time near the 
cagemate. Assessment of gene expression in 5 brain regions revealed that the SON was 
most responsive to hormone treatment, and that across brain regions, the oxytocin and 
vasopressin signaling systems were most commonly affected, a result that likely ties back 
to the behavioral results. 
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Effects of estradiol treatment on social behaviors  
Estradiol decreased USVs and interactions between familiar female cagemates  
  Studies conducted in rodents of both sexes show an increased preference 
for a novel over a familiar conspecific (Markham & Juraska, 2007; Carr et al., 1976; 
Berlyne, 1950; Bevins & Besheer, 2006). We expected to observe such a preference, and 
further predicted that it would be enhanced in the E2 group relative to the vehicle rats 
based on work conducted in other social contexts. For example, the number of USVs 
emitted by cycling, intact female rats is highest during proestrus, when E2 concentrations 
are high (Matochik et al., 1992b; Matochik et al., 1992a). Other studies in ovariectomized 
females rats have shown short-term treatment with E2 plus progesterone increased USVs 
(Matochik et al., 1992a; McGinnis & Vakulenko, 2003).  
  Contrary to this prediction, our E2-treated rats emitted significantly fewer 
total USV calls than vehicle rats on Trials 2 and 3, when the cagemates were re-
introduced following a 1-week period of separation. A possible explanation for these 
seemingly disparate outcomes is the role of E2 social memory. Studies using a model of 
resident intruder have shown that if a female rat or mouse is exposed to the same female 
intruder several times separated by intervals the resident emitted fewer calls each time, 
interpreted as indication of social memory (D’Amato & Moles, 2001; Moles et al., 2007; 
Haney & Miczek, 1993). Thus the fewer calls being emitted by the E2 compared to 
vehicle rats in the current study suggests potential differences in recognition of the 
conspecific as their previous cagemate caused by hormone treatment. This is in line with 
previous studies that have found that E2 treatment after OVX led to enhanced social 
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recognition compared to their OVX non-treated counterparts (Hlinak, 1993; Tang et al., 
2005). Beyond the resident intruder test, the context in which female USVs have been 
examined has been limited to mating behavior (Thomas & Barfield, 1985; Matochik et 
al., 1992b).  
  Thus, our current findings warrant further investigation of USVs as an 
index of social memory, and application of this type of behavioral analysis to same-sex 
interactions. Because our results for decreased calling in E2-treated rats was unexpected, 
more research is needed to better elucidate the regulatory role of estradiol on these 
complex behaviors. 
 
Estradiol had little effect on social preference in a sociability test 
  The literature on social novelty shows that rats typically spend more time 
with novel than familiar animals (Markham & Juraska, 2007; Carr et al., 1976; Berlyne, 
1950; Bevins & Besheer, 2006), although female rats have been shown to exhibit a lower 
novelty preference than males (Cyrenne & Brown, 2011). In our model using cagemates 
separated for one week, we found the opposite effect, namely, that the preference was for 
the cagemate over a novel (same-sex, same-treatment) rat. We also saw relatively modest 
effects of E2 treatment in the test for social preference and social interaction. This was 
also contrary to our original hypothesis that E2 would enhance an animal’s preference for 
the novel rat, based on research using OVX rodents given acute injections of estradiol, 
and on results from studies using receptor knockout mice (ERα, ERβ) on social behaviors 
(Hlinak, 1993; Choleris et al., 2003; Vetter-O’Hagan & Spear, 2012). The lack of novelty 
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preference could be due to our paradigm that did not enable physical contact between the 
experimental and stimulus rats. In support of this, Vetter-O’Hagan & Spear (2012) 
demonstrated that in a social interaction test where the experimental animal was able to 
freely interact with novel animals, OVX rats spent less time interacting with a novel rat 
than did their intact counterparts. 
 
Effects of estradiol treatment on gene expression in the brain 
  Five brain regions were used for qPCR profiling of a suite of genes 
involved in steroid hormone receptors, the vasopressin and oxytocin systems, other 
neuropeptides and neurotransmitters, and epigenetic modifiers. Regarding regional 
results, after correction for false discovery rate, no significant effects of E2 were found in 
the PFC. Only one gene (Pgr) was affected in the PVN. The BNST and MeA had 3 and 4 
significant genes each. The region with greatest change was the SON. Because of the 
interconnectedness of the selected brain regions, we have framed the following 
discussion around 3 functional gene families: steroid hormone signaling, vasopressin and 
oxytocin signaling, and neurotransmitters involved in social behavior.  
 
Steroid hormone receptors 
  Three steroid hormone receptor genes were significantly affected in our 
study: Pgr in the PVN (increased by E2), Esr2 in the BNST (decreased by E2), and Ar in 
the MeA (increased by E2). The increase in Pgr in the PVN of E2 compared to vehicle 
rats is congruent with the literature showing this gene’s estrogen responsiveness (Tetel & 
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Lange, 2009; Mani & Oyola, 2012). Ar, which was increased by E2 in the MeA, has 
abundant expression in this region (Simerly et al., 1990; Stanić et al., 2014). Androgen 
receptors are sensitive to the changes in sex steroid hormone levels during the estrous 
cycle in the amygdala (Feng et al., 2010). Regarding There is a high density of ERβ 
expressing cells throughout the BNST (Shughrue et al., 1997; Shughrue & 
Merchenthaler, 2001) so the down-regulation of Esr2 by E2 was not surprising.. The 
literature on the regulatory effects of estradiol on ERβ in the BNST is mixed, with some 
studies reporting downregulation (Brown et al., 1996; Gréco et al., 2001) and others no 
change after E2 treatment (Patisaul et al., 1999; Shima, Yamaguchi & Yun, 2003). E2 
regulates expression of both estrogen receptors in a region specific manner (Patisaul et 
al., 1999; Gréco et al., 2001; Zhou et al., 1995); our lack of effect of E2 on Esr1 in any 
region, and only one effect on Esr2 in the BNST, may be attributable to the longer-term 
E2 treatment to our OVX rats relative to prior work.  
 
Vasopressin and oxytocin signaling 
Oxytocin (Oxt) and vasopressin (Avp), as well as their receptors, are involved in a 
variety of social behaviors (see review papers Young, 1999; Neumann & Landgraf, 
2012). Mice whose genes for either Oxt (Choleris et al., 2003; Winslow & Insel, 2002) or 
Avp1ra receptor (Bielsky et al., 2004) have been knocked out exhibit deficits in social 
memory and social interaction.  Interestingly, similar deficits have been seen in rats with 
knockouts of either estrogen receptor (Choleris et al., 2006; Imwalle et al., 2002). 
Similarly, removal of steroid hormones by OVX led to deficits in social interaction and 
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social memory that are mitigated with administration of estradiol replacement therapy 
(Hlinák, 1993; Tang et al., 2005). 
In our gene expression work, Oxtr was upregulated by E2 in all 5 brain regions, 
but this only survived false discovery rate correction in the BNST, MeA, and SON, the 
latter regions which have previously been shown to express this receptor (Adan et al., 
1995; Elands et al., 1988; Vaccari et al., 1998). Research on Oxtr has shown that elevated 
estrogen levels during the latter phases of pregnancy and partition were associated with 
increased Oxtr expression in the BNST and SON (Meddle et al., 2007; Young et al., 
1997). Also, E2 treatment increased Oxtr expression in the MeA after 48 hours 
(Quiñones-Jenab et al., 1997) and 9 days (Patisaul et al., 2003) of treatment. In the SON, 
one study reported no changes in Oxtr across the different stages of the estrous cycle or 
pregnancy (Young et al., 1997), whereas Oxtr was increased during late gestation in rats 
(Bealer et al., 2006) and prairie voles (Ophir et al., 1013). Bealer and colleagues (2006) 
also reported that E2 treatment after OVX increased Oxtr expression in the SON 
compared to vehicle.  
  In the SON, along with Oxtr, both vasopressin (Avp) and Oxt gene 
expression were upregulated by E2 treatment. Estrogen regulates Avp and Oxt in the SON 
predominantly through the ERβ (Winslow & Insel, 2004; Hrabovszky et al, 1998), and 
ERβ is also colocalized with both nonapeptides in this region (Hrabovszky et al., 1998; 
Alves et al., 1998; Patisaul et al., 2003). However, the literature on E2 regulation of Avp 
and Oxt in the SON is mixed. Some studies showed that E2 upregulated (Roy et al., 
1999), downregulated (Shughrue et al., 2002; Van Tol et al., 1988), or had no effect on 
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expression (Peter et al., 1990; Rhodes et al., 1981). Our data add to this literature on the 
SON by showing that long-term E2 treatment up-regulates expression of genes involved 
in nonapeptide signaling. 
 
Neurotransmitters involved in social and affective behavior  
  Depression and anxiety are twice as common in women than in men 
(Wong & Licinio, 2001), and menopause is associated with increases in affective 
dysfunctions (Freeman et al., 2004; Schmidt et al., 2004; Bromberger et al., 2011). 
Estrogens are believed to play a role in anxiety and depressive behavior by modulating 
serotoninergic and dopaminergic neural systems (Morissette & Di Paolo, 1993; van de 
Kar et al., 2002; Bazzett & Becker, 1994; Lammers et al., 1999). GABA and glutamate 
neurotransmission, also implicated in these behaviors, are also estrogen-sensitive (Petty, 
1995; Brambilla et al., 2003; Hashimoto et al., 2013; Herbison, 1997; Micevych & 
Mermelstein, 2008).  
  In our study, expression of the dopamine receptor D2 (Drd2), serotonin 
receptor 1a (Htr1a), NMDA receptor subunit 2b (Grin2b), and the GABA-B receptor 1 
(Gabbr1) were downregulated by E2, a result that was specific to the SON. Although 
there is a strong literature on effects of E2 on serotonin receptors and transporters, and for 
roles of E2 in modulating affective behaviors (McQueen, Wilson & Fink, 1997; Sumner 
& Fink, 1993 & 1995, Biegon & McEwen, 1982; Raap et al., 2000; Charoenphandhu et 
al., 2011; Mize et al., 2001, Klemenhagen et al., 2006; Parks et al., 1998; Ramboz et al., 
1998, Lerer et al., 1999), little work has been conducted in the SON. It has been 
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postulated that E2 regulation of serotonin receptors may impact a women’s responses to 
serotonin modulating drugs (Fischette et al., 1983; Kendall et al., 1981; Rubinow et al., 
1998) and that combining both estrogens with SSRIs could lead to better therapeutic 
effects (Xu et al., 2009).  
The dopamine receptor D2 is the most abundant subtype in the central nervous system 
(Dailly et al., 2004), including the hypothalamus (Bouthenet et al., 1991; Mansour et al., 
1990; Meador-Woodruff et al., 1991). However, most research on E2 regulation of 
dopaminergic signaling has focused on the mesolimbic system (Roy et al., 1990; Bédard 
et al., 1983; Gordon & Perry, 1983). In addition, in striatum, E2 decreased expression of 
the D2 receptor (Lammers et al., 1999). Our result that expression of Drd2 in the SON is 
decreased by long-terms E2 treatment adds to this literature. 
 
CONCLUSION 
Our results that E2 had strong effects on genes involved in social behavioral 
regulation, especially in the SON, taken together with our results on USV 
communications, lead us to speculate that the molecular changes caused by E2 are 
associated with, or may even cause, the behavioral outcomes. It is interesting that the 
nonapeptide signaling pathways involved in social interaction and social memory, are all 
upregulated by E2, whereas neurotransmitter pathways are all down-regulated by E2. 
Clearly more work would be needed to prove a causal relationship between E2 treatment, 
effects on neural pathways, and behavior but our work is an important first step in 
identifying potential candidates.  
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The novel USV test developed for this study represents an emerging technique 
that can be used to measure social memory or behavior in other contexts (Ciucci et al., 
2008; Johnson et al., 2015; Lee et al., 2015). Translation of studies in rats may help 
inform research in women, especially those undergoing surgical or natural menopause. 
While E2 has benefits in the treatment of depression and anxiety (Zweifel & O’Brien, 
1997; Schmidt et al., 2000; Gambacciani et al., 2003) there is little research on the 
importance of the social context. In our future work, we will apply these behavioral and 
molecular measures to a preclinical model of menopause in rats. 
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Gene Name PVN BNST MeA SON PFC 
Steroid hormone receptors 
Esr1 Estrogen Receptor Alpha ------ ------ ------ 0.003ê -- 
Esr2 Estrogen Receptor Beta ------ 0.001é ------ ------ -- 
Ar Androgen Receptor ------ ------ 0.014é ------ -- 
Pgr Progesterone Receptor 0.000é ------ ------ ------ -- 
Nr3c1 
Nuclear Receptor Subfamily 3, Group C, Member 1 
(glucocorticoid receptor) 
------ ------ ------ ------ -- 
Oxytocin and vasopressin signaling 
Avp Vasopressin ------ ------ ------ 0.043é -- 
Avpr1a Vasopressin Receptor 1a ------ ------ ------ ------ -- 
Oxt Oxytocin ------ ------ ------ 0.004é -- 
Oxtr Oxytocin Receptor  ------ 0.006é 0.003é 0.038é -- 
Neurotransmission 
Drd1a Dopamine Receptor D1A ------ ------ ------ 0.034ê -- 
Drd2 Dopamine Receptor D2 ------ ------ ------ ------ -- 
Htr1a 5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled ------ ------ ------ ------ -- 
Htr2a 
5-Hydroxytryptamine (serotonin) Receptor 2A, G Protein-
Coupled 
------ ------ ------ ------ -- 
Htr2c 5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled ------ ------ ------  -- 
Oprm1 Opioid Receptor, Mu 1 ------ ------ ------ ------ -- 
Oprk1 Opioid Receptor, Kappa 1 ------ ------ ------ ------ -- 
Oprd1 Opioid Receptor, Delta 1 ------ ------ ------ ------ -- 
Grin1 Glutamate Receptor, Ionotropic, N-methyl D-aspartate 1 ------ ------ ------ ------ -- 
Grin2a Glutamate Receptor, Ionotropic, N-methyl D-aspartate 2A ------ ------ ------ ------ -- 
Grin2b Glutamate Receptor, Ionotropic, N-methyl D-aspartate 2B ------ ------ ------ 0.026ê -- 
Grin2c Glutamate Receptor, Ionotropic, N-methyl D-aspartate 2C ------ ------ ------ ------ -- 
Grin2d Glutamate Receptor, Ionotropic, N-methyl D-aspartate 2D ------ ------ ------ ------ -- 
Gria1  Glutamate Receptor, Ionotropic, AMPA 1 ------ ------ ------ ------ -- 
Gria2 Glutamate Receptor, Ionotropic, AMPA 2 ------ ------ ------ ------ -- 
Gabbr1 GABA B Receptor 1 ------ ------ ------ 0.045ê -- 
Gabbr2 GABA B Receptor 1 ------ ------ ------ ------ -- 
Growth factor signaling 
Bdnf Brain-Derived Neurotrophic Factor ------ ------ ------ ------ -- 
Igf1 Insulin-Like Growth Factor 1 ------ ------ ------ ------ -- 
Igf1r Insulin-Like Growth Factor 1 Receptor ------ ------ ------ ------ -- 
Egr1 Early Growth Response 1 ------ ------ ------ ------ -- 
Epigenetic signaling 
Hdac1 Histone Deacetylase 1 ------ ------ ------ ------ -- 
Hdac2 Histone Deacetylase 2 ------ ------ ------ 0.003ê -- 
Hdac4 Histone Deacetylase 4 ------ ------ ------ 0.008ê -- 
Dnmt1 DNA (cytosibe-5-)-methyltransferase 1 ------ ------ ------ ------ -- 
Dnmt3a DNA (cytosibe-5-)-methyltransferase 3 alpha ------ 0.014é ------ ------ -- 
Dnmt3b DNA (cytosibe-5-)-methyltransferase 3 alpha ------ ------ ------ ------ -- 
Other 
Crh Corticotropin Releasing Hormone ------ ------ ------ ------ -- 
Foxp2 Forkhead Box P2 ------ ------ ------ 0.040ê -- 
Foxp1 Forkhead Box P1 ------ ------ 0.002é ------ -- 
Nlgn3 Neuroligin 3 ------ ------ ------ ------ -- 
Shank1 SH3 and Multiple Ankyrin Repeat Domains 1 ------ ------ ------ ------ -- 
Tac3 Tachykinin 3 ------ ------ 0.010ê ------ -- 
Table 2.1: List of 42 selected genes 
List of 42 selected genes quantified using Taqman low-density arrays (does not include 3 house-keeping 
genes, Gapdh, Rpl13a, and 18s). P-values are shown for genes that had a significant effect of treatment 
after false-discovery rate correction.  Three genes were non-detectable and are not listed above: Dbh, 
Slc6a3, and Slc6a4. Estrogen effects are shown with colored arrows: up-regulation by estradiol, compared 
to vehicle, is shown in green up-arrows, and down-regulation in red down-arrows. 
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CHAPTER 4: THE EFFECTS OF TIMING AND DURATION OF 
ESTRADIOL TREATMENT ON SOCIAL BEHAVIOR AND GENE 
EXPRESSION IN AGING FEMALE RATS 
 
ABSTRACT 
This study focused on testing the effects of timing and duration of estradiol (E2) 
replacement on social behavior and gene expression in ovariectomized aging female rats. 
Communication, social memory and preference were examined at 2 different time points 
(3-months & 6-months) using an ultrasonic vocalization (USV) test and a sociability test 
in the social context of female-female cagemates. A 48-gene qPCR array was used to 
look at underlying neurobiological molecular changes in 5 brain regions. At the 3-month 
testing period 3-months of estradiol treatment significantly decreased the number of 
USVs emitted and decreased the amount of time spent interacting. No differences in 
number of USVs emitted were observed between the 4 treatment groups at the 6-month 
testing period. There were few effects of timing and duration of E2 in the sociability test. 
For gene expression, different patterns of timing and duration of estradiol were seen 
across the 5 brain regions. With the majority of changes seen in genes involved in 
regulating social behavior such as neuropeptides (Oxt, Oxtr & Avp), neurotransmitters 
(Drd1, Drd2, Htr2a, Grin2d & Gabbr1), and steroid hormone receptors (Esr2, Ar, Pgr). 
These data suggest that the timing and duration of E2 treatment have specific effects on 
social behavior and expression of target genes involved in the regulation of these 
behaviors.  
 87 
INTRODUCTION 
 All women will experience menopause during their lifetime, be it naturally or 
surgically. The loss of ovarian hormones during menopause is associated with a variety 
of physiological changes that sometimes impair the quality of life. Hormone replacement 
therapy (HRT) is currently the most commonly used treatment for these menopausal 
symptoms. Since the early termination of the Women’s Health Initiative (WHI) due to a 
small but significant increase in certain adverse incidents in women taking hormone 
therapy (Rossouw et al., 2002; Manson et al., 2013), women and physicians have been 
left wondering whether HRT should be taken and if so, when and for how long. 
Subsequent evaluations of the WHI suggested that there may be a “critical window” in 
which HRT is beneficial but after which it can become detrimental (Klaiber et al., 2005; 
Bhupathiraju & Manson, 2014). However, despite much speculation, few preclinical 
studies have directly tested the critical window hypothesis (Gibbs, 2000; Daniel et al., 
2006).  
 While the most common neurobiological symptoms of perimenopausal women 
are hot flashes and sleep disturbances, a subset of women experience neurobehavioral 
changes such as anxiety and depression, sometimes leading to problems in interpersonal 
relationships and a lack of desire to interact socially (Uguz et al., 2011; Deeks & 
McCabe, 2004; Lanza di Scalea et al., 2012; Schmidt et al., 2000). Animal studies show 
that both the neural circuits and neurotransmitters involved in the control of social 
behavior, and the behaviors themselves, are subject to age- and hormone (especially 
estradiol) regulation. For example, with aging, rodents show increased anxiety and 
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decreased social interaction (Salchner et al., 2004; Guan & Dluzen, 1994; Boguszewski 
& Zagrodzka, 2002). Hormones are also important, as ovariectomy in female rats leads to 
decreased social interaction independent of age (Hlinák, 1993; Tang et al., 2005). Mice 
lacking either of the nuclear estrogen receptors show deficits in social interaction and 
social memory (Choleris et al., 2006; Egashira et. al, 2007). Short-term estradiol (E2) 
replacement in mature adult female rats improves social memory and increases social 
interaction (Hlinák, 1993; Tang et al., 2005). The neurotransmitter systems involved in 
regulating these behaviors, including serotoninergic and dopaminergic neurons, are 
highly sensitive to E2 (Morissette & Di Paolo, 1993; van de Kar et al., 2002; Bazzett & 
Becker, 1994). The neuropeptides oxytocin and vasopressin, and their receptors, involved 
in social behavioral regulation, are also E2-sensitive (Winslow & Insel, 2004; 
Hrabovszky et al, 1998; Quiñones-Jenab et al., 1997; Axelson & van Leeuwen, 1990; 
Garcia et al., 2016). 
 The current study sought to test the critical window hypothesis on the social 
behavioral phenotype, and to determine how underlying neurotransmitter systems in a 
defined neural network are altered by differential treatment regimes. Social behaviors 
were tested using a novel test of ultrasonic vocalizations (USVs) as an index of 
communicative and affective state, and a test of social interaction and memory (Tang et 
al., 2005; D’Amato & Moles, 2001; Moles et al., 2007; Hlinak, 1993). The 
neuromolecular phenotype of these animals was assessed using low-density qPCR arrays 
of relevant brain regions. An important feature of our model is that work was conducted 
on middle-aged female rats, as an age-appropriate model for perimenopausal women.  
 89 
MATERIAL AND METHODS 
Animals and Husbandry 
 All animal procedures were conducted in agreement with The Guide for the Care 
and Use of Experimental Animals following protocols approved by The University of 
Austin IACUC committee and NIH standards. Aged adult (AG, 11-12 months, retired 
breeders) female Sprague Dawley rats (Harlan) were purchased for this project. At the 
time of arrival animals were double housed and allowed to acclimate to their new 
environment for 2 weeks prior to surgery. Animals were given water and food ad libitum 
and kept on a 12-hour dark cycle (lights on at 0700). During the acclimation period 
estrous cyclicity was monitored daily by vaginal lavage of sterile saline. Only animals 
that had a regular 4-5 day cycles were used for the experiment. After the acclimation 
period all animals underwent ovariectomy (OVX) surgery under isofluorane inhalation 
anesthesia. At the start of the surgery each animal was given a single injection of 
Rimadyl (5 mg/kg) for pain. Bilateral dorsolateral incisions were made through the skin, 
muscle, and peritoneum, and the ovaries were ligated and removed. Muscles were sutured 
and wound clips used to close the skin. At the time of surgery animals were implanted 
subcutaneously between the shoulder blades with capsules containing either 100% 
cholesterol (Veh) or 5% 17β-estradiol / 95% cholesterol (E2) at the time of surgery. Three 
months after the OVX surgery animals were anesthetized again. Half of the animals had 
their capsules checked to verify that they were intact. The other half of the rats had their 
treatments switched (E2 to vehicle, or vehicle to E2). Groups (Figure 3.1) are 
subsequently referred to as V6 (6 months vehicle, n = 14), E6 (6 months E2, n = 14), 
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V3/E3 (3 months vehicle, switched to 3 months E2, n = 14) and E3/V3 (3 months E2, 
switched to 3 months vehicle, n = 14). Rats were pair-housed, with both cagemates 
assigned to the same treatment group. 
 
 
Figure 3.1: Rat model  
Rat were 11 months of age at the time of OVX, and received either vehicle (cholesterol, 
VEH) or 17β-estradiol capsule implantation at the time of surgery. Groups 1 & 2 received 
treatment for a duration of 6-months. Groups 3 & 4 were the “switch” groups that 
received either VEH or E2 initially at the time of OVX and were switched to the opposite 
treatment after 3-months, and continued on the new treatment for a 3-month duration. 
Behavioral testing occurred twice, once at the end of the 3-month period, and again at the 
6-month period. 
 
 
Behavioral paradigms 
 Prior to the start of behavioral testing all animals were separated from their 
cagemates for one week and singly housed. Two rounds of behavioral testing were 
performed for this study, the first towards the end of the first 3-month period, and the 
second round after 6-months of treatment (3 months after switching hormone, or 
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verifying the capsule in rats for which the same treatment was continued. This allowed us 
to examine the effects of timing and duration of hormone replacement therapy on the 
same animals’ behavior.  
 
Ultrasonic vocalization test (USV)  
Following a week of separation, USV testing was conducted on the cagemates 
over 2 consecutive days in a total of four 5-minute trials, during which USVs were 
recorded. On day 1 each rat was habituated to a rectangular Plexiglas apparatus (23L x 
29W x 40H cm) for 5 minutes (Trial 1). On day 2, rats were given three sequential 5-
minute trials, referred to as Trials 2, 3, and 4. In Trial 2, the apparatus was fitted with a 
removable plastic perforated grid that bisected the apparatus. The cagemates were placed 
into the apparatus separated by the grid. This was the first re-introduction of the rats after 
the week of isolation; they could engage in limited interactions across the grid but did not 
have physical contact. For Trial 3, the perforated grid was removed and the cagemates 
were allowed to freely interact with one another. Videorecording of this trial was 
performed, and recordings used to quantify activity, time interacting, and anogenital 
investigation of the partners. For Trial 4 the cagemates were separated into 2 identical 
apparati and recorded separately. Upon completion of Trial 4 on day 2, all animals were 
housed separate from their cagemates until they completed the sociability test. 
UltraSoundGate hardware and software was used to record ultrasonic 
vocalizations during all four trials. Saslab Pro (Avisoft, Germany) was optimized so that 
we were able to use it to automatically detect and quantify calls. We found that all calls 
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fell in the range between 30 and 70kHz. We used these data to further differentiate calls 
into frequency modulated (FM) or non-frequency modulated (NFM). A call was 
considered to be a frequency modulated if it had more than a 9kHz change in frequency. 
Due to the inability to distinguish which rat was calling when the cagemates were 
together in the apparatus during Trials 2 and 3, we treated each set of cagemates as a unit 
when performing analysis. Therefore, when the animals were recorded separately during 
Trials 1 and 4, their calls were summed to be comparable to results in Trials 2 and 3.  
USV behavior that was video recorded during Trial 3 was hand scored by observer that 
was blind to the treatment of the animals. If the animals we participating in meaningful 
contact such as nose-touching or grooming it was recorded as time interacting. Time 
active was the number of times each animal crossed the centerline of the chamber with all 
four limbs.  
Statistics were conducted using SPSS (Version 23). The data sets from the USV 
test did not meet assumptions of normality and variance even after transformations were 
performed. Therefore, non-parametric statistics were used. Data were tested for outliers 
using the Grubb’s outlier test, and confirmed outliers were excluded from final analysis. 
Data were analyzed for the total number of calls, as well as for FM and NFM calls. Due 
to the non-normality both the data from the 3-month and 6-month testing period were 
analyzed using a Mann-Whitney tests to examine the effects of treatment during each 
trial. For all of these analyses, alpha was set at 0.05. In addition, a false discovery rate 
correction (q-value), Benjamini-Hochberg method (Benjamini & Hochberg, 1995), was 
used to correct for the multiple comparisons.  
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Sociability test  
We used a 3-compartment apparatus to test discrimination and/or preference of an 
experimental rat for her cagemate vs. an unfamiliar same-treatment rat. There were 2 
consecutive days of testing. On day 1, one of the cagemates was randomly chosen to be 
the experimental rat. This rat was allowed to habituate for 5 minutes to a Stoelting 
Plexiglas three-chamber apparatus (100L x 100W x 34.5H cm total), which contained 
two holding cages in each corner of the side chambers. Once habituation was completed 
the experimental rat was placed back into its home cage. Her cagemate was placed into 
one of the holding cages, and a novel rat of the same sex, age, and treatment was placed 
into the other holding cages. The placement of rats was randomized. Then, the 
experimental animal was placed into the center chamber of the apparatus and allowed to 
explore the entire apparatus for 5 minutes. Rats were singly housed overnight. On day 2 
the original experimental rat was now used as a stimulus rat, and her cagemate used as 
the experimental rat. A new rat (same treatment but different from the novel rat on day 1) 
was used as the novel rat on day 2. The experimental rat was given 5 minutes to explore 
the entire apparatus. On both days, the experimental rats’ movement and behavior were 
tracked using Any-Maze software (Stoelting Co., Wood Dale, IL). At the end of day 2 of 
sociability testing all animals were rehoused with their cagemates until time of euthanasia 
1 week later. 
Statistics were conducted using SPSS (Version 23). For data that met assumptions 
of normality a repeated measures test was performed to determine effects of treatment on 
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the behavioral measures. Data that did not meet assumptions a square root transformation 
was used followed by a repeated measures test. However, most of the data did not meet 
assumptions even after transformations; therefore a Mann-Whitney test was used to 
examine difference in each round and a Wilcoxon signed rank test was used to examine 
differences between the 3-month and 6-month testing periods. Alpha was set at 0.05 and 
a false discovery rate correction (q-value), Benjamini-Hochberg method (Benjamini & 
Hochberg, 1995), was used to correct for the multiple comparisons.  
 
Brain tissue processing  
 Six months after OVX and a week after behavioral testing was completed, 
animals were euthanized between 1330-1600 hours by rapid decapitation; all animals 
were 17 months of age. Trunk blood was collected and the brains were removed, chilled 
on ice, and sectioned coronally at 1 mm increments using an ice-cold stainless steel brain 
matrix. Brain sections were stored overnight at 4°C in cryogenic storage vials that 
contained RNAlater (Life technologies, Grand Island, NY). The next day, the sections 
were mounted onto chilled slides. Bilateral brain punches were taken from 5 regions 
under a dissecting microscope using Palkovits punches and the Paxinos and Watson 
(2009) rat brain atlas (all coordinates are based on that atlas). The paraventricular nucleus 
(PVN) punch (1.22 mm diameter) began rostrally at ~Bregma = -0.84 mm, and extended 
caudally 1 mm. The supraoptic nucleus (SON) punches (0.96 mm diameter) started 
rostrally at ~Bregma = -0.60 mm and extended caudally for 1 mm. The medial amygdala 
(MeA) punches (1.22 mm diameter) began rostrally at ~Bregma = -1.56 mm, and 
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extended caudally 1mm. The bed nucleus of the stria terminalis (BNST) punches (0.96 
mm diameter) started rostrally at ~Bregma = 0.00 mm, and extend caudally for 1mm. The 
prefrontal cortex (PFC) punches (1.22 mm diameter) began rostrally at ~Bregma = 4.20 
mm, and extend caudally for 1mm. Brain punches were placed in frozen RNAse free 
Eppendorf tubes and stored at -80°C until time of PCR. Trunk blood that was collected at 
euthanasia was allowed to clot for 30 minutes, centrifuged (2300 X g) for 5 minutes, and 
serum collected and stored at -80°C in Eppendorf tubes until time of hormone assays.  
 
Real-time PCR assays and analysis  
 Using an Allprep RNeasy mini kit (Qiagen, Valencia, California), according to 
the manufacturer’s protocol, RNA was extracted from frozen PVN, SON, MeA, BNST, 
and PFC punches of individual rats. Using an Agilent 2100 Bioanalyzer (Agilent, Santa 
Clara, CA) the quality of RNA was validated (RIN values were from 8.70 and 9.90) and 
quantity of RNA was assessed using a GloMax-Multi Detection System (Promega, 
Madison, WI). A high-capacity cDNA reverse transcription kit (Life Technologies, 
Grand Island, NY) was used to convert mRNA to single-stranded cDNA; all samples 
were then stored at -80°C until use. A customized rat Taqman low-density array (TLDA) 
Microfluidic 48-gene real-time PCR cards (Applied Biosystems) was used. Real-time 
PCR was performed using Taqman universal mastermix (Life Technologies, Grand 
Island, NY) and detected on a ViiA7 Real time PCR machine (Applied Biosystems, Life 
Technologies, Grand Island, NY) with the following run parameters: 0°C for 2 minutes, 
95°C for 10 minutes, 45 cycles of 95°C for 15 seconds, and 60°C for 1 minute. 
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The genes for the assay were chosen specifically for this study, based on their 
roles in the neurobiology of aging, social behavior, and/or regulation by steroid hormones 
(45 genes of interest and three normalizing genes; Supplementary Table 1). Relative 
expression was determined for each sample using the comparative cycle threshold 
method (Pfaffl, 2001; Schmittgen and Livak, 2008). All samples were normalized to the 
geometric mean of the housekeeping genes Gapdh, Rpl13a, and 18s and then calibrated 
to the median δ-cycle threshold of the vehicle treated group. Samples that amplified at or 
above 35ct were excluded from analysis. 
For gene expression data, statistics were performed using relative expression 
values for each sample. Data was tested for outliers using the Grubbs’ outlier test and 
confirmed outliers were excluded from analysis. If data did not meet assumptions of 
normality they were transformed using either natural log or square root transformation. 
Data that met assumptions before or after transformation were analyzed using a one-way 
ANOVA with a Tukey HSD post hoc. Otherwise, a non-parametric analysis was 
performed using a Kruskal-Wallis test followed by a Mann-Whitney test to examine 
differences between each group. For all of these analyses, alpha was set at 0.05 and a 
false discovery rate correction (q-value), Benjamini-Hochberg method (Benjamini & 
Hochberg, 1995) was used to correct for multiple comparisons. 
 
Estradiol hormone assay 
 Levels of serum estradiol (E2) were determined by radioimmunoassay 
(Ultrasensitive Estradiol RIA, Cat No DSL4800, Lot # 150622C, Beckman Coulter, 
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Pasadena, CA), according to the manufacturer’s directions. A single assay was used for 
all the samples. Samples were run in duplicates with volumes of 100µl of serum. Assay 
sensitivity was 2.2 pg/ml and intrassay C.V. was 1.30%. Both E6 (34 + 5) and V3/E3 (24 
+ 5) had significantly (p < 0.01) higher concentrations of estradiol than both the V6 (16 + 
2) and E3/V3 (14 + 1).   
RESULTS 
Ultrasonic vocalization test 
USV calls  
 In the first series of USV tests, conducted 3 months after OVX and hormone 
treatment, there were significant differences between E2 and vehicle treated animals in 
total calls on Trials 2 and 3. The E2 animals emitted significantly fewer calls than the 
vehicle rats (Fig. 3.2A). When subdivided into FM and NFM calls, vehicle animals 
emitted significantly more FM calls than E2 animals on Trial 2 (Fig. 3.2B) of testing. In 
addition, vehicle animals made significantly more NFM calls on Trials 2 and 3 (Fig. 
3.2C).  
There were no significant differences in the number of total (Fig. 3.2A) and NFM 
(Fig. 3.2C) USVs emitted between any of the treatment groups at the 6-month testing 
period. Analysis of FM calls showed there were significant effects of treatment during 
Trial 3 (Fig. 3.2B), when V6 animals emitted significantly more USVs than E6 and 
V3/E3 animals. E3/V3 animals made significantly more calls than E6 and V3/E3 animals. 
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USV behavior 
 Trial 3 of the USV test was videotaped, and three behaviors were scored off of the 
tapes; 1) time spent interacting, 2) number of anogenital investigations, and 3) activity. 
At the 3-month testing period, vehicle treated animals spent significantly more time 
interacting with their cagemate than did E2 treated animals (Fig 3.3A). There were no 
significant differences between the two treatment groups on anogenital investigation (Fig 
3.3B) or time active (Fig 3.3C). At the 6-month testing period the E3/V3 treated animals 
engaged in significantly less anogenital investigation than did V3/E3 and E6 treated 
animals (Fig 3.3B). There were no significant differences between any of the 4 treatment 
groups on time spent interacting (Fig 3.3A) or activity (Fig 3.3C).  
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Figure 3.2: Data from ultrasonic vocalization test 
 
Numbers of USV calls are shown the 3-month and 6-month testing periods. Hash marks 
on the x-axis indicate the 3-month gap between the two testing periods. The legend 
illustrates the transition of treatments from the 3-month to the 6-month testing period. 
Note that the y-axis varies across graphs. A) The total number of USVs was significantly 
higher in V3 than E3 animals on Trials 2 and 3 at the 3-month testing period. There were 
no differences between treatment groups at the 6-month testing period. B) For FM calls, 
the V3 group emitted significantly more calls than the E3 animals on Trial 2. At the 6-
month testing period both the V6 and E3/V3 groups emitted significantly more calls than 
the E6 and V3/E3 groups during Trial 3. C) Non-frequency modulated (NFM) calls were 
higher in V3 than E3 rats on Trial 2. No differences were seen between treatment groups 
at the 6-month testing period. A-C: Data are shown + SEM. Significant differences are 
shown as double asterisk for p values less than 0.01 (** = p < 0.01). 
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Figure 3.3: Behavior data from Trial 3 of ultrasonic vocalization test at the 3-month and 
6-month testing periods 
 
The hash marks on the x-axis indicate the 3-month gap between the two testing periods. 
The legend illustrates the transition of treatments from the 3-month to the 6-month testing 
period. Note that the y-axis varies across graphs. A) Time interacting at the 3-month 
testing period was significantly lower in the E3 group compared to V3. No differences 
were observed between groups at the 6-month testing period. B) No differences in time 
spent engaging in anogenital investigation were seen at the 3-month testing period. At the 
6-month testing period the E3/V3 spent significantly more time engaging in anogenital 
investigation than the other 3 groups. C) No differences in activity, measured by the 
number of line crosses, were seen in either test. A-C: Data are shown + SEM. Significant 
differences are shown as single asterisk for p values less than 0.05 (* = p < 0.05) and 
double asterisk for p values less than 0.01 (** = p < 0.01). 
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Sociability test  
 There were few treatment effects detected in the sociability test; only significant 
results are presented. Estradiol treated animals at the 3-month testing period spent more 
time immobile (Fig 3.4A), traveled farther (Fig 3.4B), and moved significantly more 
quickly (Fig 3.4C) than vehicle treated animals. Percentage of the social time spent with 
the novel animal was calculated by dividing time spent with the novel animal by the time 
spent with the novel animal plus the time spent with the cagemate. When analyzing the 
differences between the two treatment groups on novelty preference we found that E2 
(64% + 7%) animals spent a significantly larger portion of their social time with the 
novel rat over the cagemate than did the vehicle (40% + 7%) treated animals. The only 
significant finding from the 6-month testing period was the amount of time spent with the 
stimulus animals. V6 treated animals spent significantly more time in proximity to their 
cagemate than they did with the novel animal (Fig 3.5).   
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Figure 3.4: Sociability data (1/2) 
 
The hash marks on the x-axis indicate the 3-month gap between the two testing periods. 
The legend illustrates the transition of treatments from the 3-month to the 6-month testing 
period. Note that the axes vary across graphs. A) Total time spent immobile was 
significantly greater in the V3 than the E3 group at the 3-month testing period. B) Total 
distances traveled were significantly higher in the E3 group than the V3 group at the 3-
month testing period. C) The average speed of the E3 groups was significantly faster than 
the V3 group at the 3-month testing period. There were no treatment differences for any 
of these parameters at the 6-month testing period. Data are shown + SEM. Significant 
differences are shown as double asterisk for p values less than 0.01 (** = p < 0.01). 
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Figure 3.5: Sociability data (2/2) 
 
Sociability results are shown for the total time spent in proximity to the stimulus rats 
(cagemate vs. novel). The hash marks on the x-axis indicate the 3-month gap between the 
two testing periods. No differences between the V3 and E3 groups were seen at the 3-
month testing period. At the 6-month testing period only the V6 group showed a 
preference for either of the stimulus rats, spending significantly more time with their 
cagemate than the novel rat. Significant differences are shown as single asterisk for p 
values less than 0.05 (* = p < 0.05). 
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Gene expression  
Gene expression was measured at the end of the study, from brains collected 1 
week after behavioral testing was completed at the 6-month period. A summary of 
significant effects of treatment for the five regions, BNST, SON, PFC, PVN and MeA, is 
provided in Table 3.1. All genes reported as significantly affected by treatment were 
identified following false discovery rate correction for multiple comparisons. 
Supplemental Table 2.1 lists all of the genes on the customized TLDA qPCR card. 
 
Bed nucleus of the stria terminalis 
 Only one gene, oxytocin receptor (Oxtr), was significantly affected in the BNST. 
There was an effect of timing and duration of treatment: Oxtr was lower in the E3/V3 rats 
compared to V6 and V3/E3 (Fig 3.6A, p < 0.05, p < 0.01, respectively).  
 
Supraoptic Nucleus 
 Dopamine receptor D2 (Drd2, Fig 3.6B, p < 0.05) was lower in V3/E3 rats 
compared to the V6 and E6 rats. Igf1 expression was lower in the E3/V3 rats compared to 
V6 and E6 animals (Fig 3.6C, p < 0.01, p < 0.05, respectively). The E3/V3 group had 
lower Igf1 than the V6 group (p < 0.05). 
 
Prefrontal cortex 
In the PFC, 4 genes had significant changes in gene expression in relation to 
timing and/or duration of E2 treatment. Oxtr expression was higher in the E6 treatment 
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compared to V6 rats (Fig 3.7A, p < 0.05). Vasopressin receptor 1a (Avpr1a) was higher 
in E6 than both V6 and E3/V3 animals (Fig 3.7B, p < 0.01, p < 0.05, respectively). 
Estrogen receptor beta (Esr2) expression was decreased in the E3/V3 treatment compared 
to the V6 group (Fig 3.7C, p < 0.01). Brain derived neurotrophic factor (Bdnf) was lower 
in both 6-month treated groups compared to the two switch groups (Fig 3.7D, p < 0.01). 
 
Paraventricular nucleus 
 Eight genes were affected in the PVN. For most of these genes, expression was 
higher in one or both groups with E2 on board at the time of euthanasia, namely, the 
V3/E3 and/or the E6 groups. For both Oxtr and Tac3 [Fig 3.8A (p < 0.01), 3.8H (p < 
0.05), respectively] expression was higher in the V3/E3 than the V6 group. For Oxt, the 
E6 group had higher expression than the V6 or the V3/E3 group (Figs 3.8B, p < 0.05). 
Similar gene expression patterns were seen for Ar, Pgr, and Crh, all of which had highest 
expression in the V3/E3 rats (Figs 3.8C, D, and E, respectively). Specifically, Ar was 
higher in V3/E3 than in V6 or E6 rats (p < 0.01, p < 0.05, respectively). Both Pgr and 
Crh expression were higher in the V3/E3 than V6 and E3/V3 rats (p < 0.01, p < 0.05, 
respectively). For those two genes, the E6 group also had higher expression than the V6 
group (p < 0.01). DNA methyltransferase 3a (Dnmt3a) expression was higher in E3/V3 
compared to V3/E3 animals (Fig 3.8F, p < 0.05). Early growth response 1 (Egr1) was 
higher in E3/V3 than V6 animals (Fig 3.8G, p < 0.05).  
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Medial amygdala 
  Twelve genes were affected by timing and duration of hormone treatment in the 
MeA, nearly all with unique expression patterns. Oxt was higher in the E3/V3 rats 
compared to V6 and V3/E3 (Fig 3.9A, p < 0.05, p < 0.01, respectively). Avp was highest 
in the E3/V3 rats, and significantly greater than in either 6-month treatment group (Fig 
3.9B, p < 0.05). For Ar, E3/V3 rats had higher expression than V6 rats (Fig 3.9C, p < 
0.01). The dopamine receptors D1 and D2 [Fig 3.9D (p < 0.01), 9E (p < 0.05), 
respectively] had highest expression in the V6 rats, levels of which were significantly 
different from the V3/E3 animals, the latter having the lowest expression. In addition, for 
Drd1, the E6 and E3/V3 rats had higher expression than the V3/E3 rats (p < 0.05, p < 
0.01, respectively). The serotonin receptor 2a (Htr2a, Fig 3.9F) and opioid receptor delta 
1 (Oprd1, Fig 3.10C) had the same expression pattern, with levels higher in rats with 
vehicle on board at the time of euthanasia (V6, p < 0.05 & E3/V3, p < 0.01) compared to 
E6. GABA B receptor 1 (Gabbr1, Fig 3.10A) was higher in E6 than V3/E3 (p < 0.05). 
Grin2d had a complex expression pattern (Fig 3.10B), with expression higher in the 
groups with vehicle on board compared to the E2 on-board groups (p < 0.05). The two 
DNA methyltransferases, Dnmt1a (Fig 3.10D) and Dnmt3a (Fig 3.10E), as well as the 
glucocorticoid receptor Nr3c1 (Fig 3.10F) had highest expression in the E3/V3 groups 
relative to the E6 and/or V3/E3 animals (p < 0.01).  
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Figure 3.6: Relative gene expression data for the BNST and SON 
 
 Note that the scale of the y-axis varies depending on the gene. Data are shown + SEM. 
Significant differences are shown as single asterisk for p values less than 0.05 (* = p < 
0.05) and double asterisk for p values less than 0.01 (** = p < 0.01). 
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Figure 3.7: Relative gene expression data for the PFC  
 
Note that the scale of the y-axis varies depending on the gene. Data are shown + SEM. 
Significant differences are shown as single asterisk for p values less than 0.05 (* = p < 
0.05) and double asterisk for p values less than 0.01 (** = p < 0.01). 
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Figure 3.8: Relative gene expression data for the PVN  
 
Note that the scale of the y-axis varies depending on the gene. Data are shown + SEM. 
Significant differences are shown as single asterisk for p values less than 0.05 (* = p < 
0.05) and double asterisk for p values less than 0.01 (** = p < 0.01). 
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Figure 3.9: Relative gene expression data for the MeA (1/2) 
 
Note that the scale of the y-axis varies depending on the gene. Data are shown + SEM. 
Significant differences are shown as single asterisk for p values less than 0.05 (* = p < 
0.05) and double asterisk for p values less than 0.01 (** = p < 0.01). 
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Figure 3.10: Relative gene expression data for the MeA (2/2) 
 
Note that the scale of the y-axis varies depending on the gene. Data are shown + SEM. 
Significant differences are shown as single asterisk for p values less than 0.05 (* = p < 
0.05) and double asterisk for p values less than 0.01 (** = p < 0.01). 
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DISCUSSION 
 This study focused on how the timing and duration of estradiol therapy affected 
the brain and social behavior of aged female rats, to test the “critical window” hypothesis 
of hormone treatment for menopause. A specific goal of this work was to provide 
empirical evidence from a preclinical model that could be used to inform decisions about 
hormone treatments and to help address the limitations from the Women’s Health 
Initiative. Our results showed that there are indeed specific timing and duration effects of 
E2 treatment on social behavior and gene expression. For our test of social 
communications as measured by USV emissions, E2 treated animals called much less, 
and showed a decrease in the amount of time spent interacting with one another, at the 3 
month post-OVX testing period. This treatment effect was not observed at the 6-month 
testing period, suggesting that a longer duration of hormone in the context of increasing 
age changed this behavior. Gene expression assessment showed that there were unique 
patterns of timing and duration of estradiol in the 5 brain regions, with the majority of 
changes observed in the MeA and PVN.  
 
Timing and duration of estradiol treatment on social interactions  
USV calls and behaviors were decreased by E2 treatment at 3 but not 6 months of testing 
 At the 3-month behavioral testing period, estradiol treated animals emitted 
significantly fewer total, frequency-modulated, and non-frequency modulated calls in the 
USV test. However, this effect of treatment was not observed at the 6-month testing 
period. The amount of time animals spent interacting with one another was also lower in 
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the E2 animals compared to vehicle rats at 3 but not 6 months. The differences between 
results in the first vs. the second set of testing periods may be attributable to the age at 
testing (14 vs. 17 months), the possible influence of prior experience in the behavioral 
test, and the nature (duration and timing) of hormone treatments. Since this was the first 
experiment to conduct this type of testing, future research is needed to differentiate 
between these possibilities, which are not mutually exclusive. 
 The literature examining the effects of estradiol on female USVs is limited, with 
studies focusing on short-term E2 treatment or stages of the estrous cycle. It was reported 
that more USVs were emitted during the late proestrus stage, when E2 and progesterone 
are highest during the reproductive cycle (Matochik et al., 1992b; Matochik et al., 
1992a). In addition, short-term E2 treatment after OVX in female rats increases total 
numbers of USVs emitted (Matochik et al., 1992b; McGinnis & Vakulenko, 2003). 
Though these studies show that estradiol facilitates production of USVs these studies did 
not look at familiar female-to-female interactions and the duration of treatment was 
significantly shorter compared to the long-term E2 treatment used in the current study. 
In parallel with the current report, we conducted a study using mature adult 
female rats, OVX at 4 months and given E2 or vehicle for 3 months, at which time they 
were tested for USV calls and interactions at 7 months of age (Garcia et al., unpublished). 
Those results, showing decreased USV calls in the E2 rats, were comparable to our 
current results from aging females tested at 14 months of age. However, we did not 
expect this effect to disappear when we tested the animals at the 6-month testing period, 
essentially irrespective of the mode (timing, duration) of hormone treatment.  
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It is interesting to consider the USV results at the 3-month testing period in light 
of behavioral outcomes scored in the same trial, when cagemates were first introduced 
and allowed to interact freely. The E2 animals showed less time interacting, similar to our 
results from the other study on mature rats (Garcia et al., unpublished). Taken in 
conjunction with the decrease in total number of USVs emitted, this behavioral 
phenotype suggests the possibility that E2 rats are demonstrating a form of social 
memory. Published studies in mice and rats that used a resident intruder test as well as a 
social recognition memory test reported that compared to vehicle, animals treated with 
E2 emitted significantly fewer calls and interacted less with a conspecific if it had been 
previously introduced to them recently; this was interpreted as the E2 animals having 
greater social memory (Tang et al., 2005; D’Amato & Moles, 2001; Moles et al., 2007; 
Hlinak, 1993). The lack of this effect at the 6-month testing period could be due a loss in 
sensitivity to the hormone, increased age (14 vs. 17 months), or both. With aging, there is 
increased anxiety and decreased social interaction compared to younger counterparts 
(Salchner et al., 2004; Guan & Dluzen, 1994; Boguszewski & Zagrodzka, 2002). In 
studies of cognitive behavior they found that delaying estradiol treatment in aged rats did 
not enhance spatial memory whereas young rats still show enhanced spatial memory up 
to 5-months post OVX (Gibbs, 2000; Daniel et al., 2006). 
Furthermore, our study entailed testing rats twice, thereby introducing the 
potential effect of behavioral experience on the outcomes observed in the second round 
of testing. The fact that hormone effects appear to be blunted may represent habituation 
to the testing paradigm. 
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The typical social preference for a novel over a familiar rat is not seen in our test of social 
interactions among cagemates, and is not strongly influenced by E2. 
 Based on previous research on social novelty in rodents we hypothesized that our 
rats, irrespective of treatment, would spend more time with the novel rather than familiar 
animals (Markham & Juraska, 2007; Carr et al., 1976; Berlyne, 1950; Bevins & Besheer, 
2006). Contrary to this prediction, rats tended to spend more time with their cagemate, or 
spent equal time with the 2 stimulus animals. Taking into account the findings from the 
3-month and 6-month testing period it appears that in order for animals to display a 
novelty preference, as calculated by percentage of the social time spent with the novel 
animal, estradiol treatment must be given immediately at the time of OVX for a 3-month 
duration and E2 must be circulating at the time of testing. This indicates that timing and 
duration of estradiol therapy are important for this particular behavior because animals 
from the E6, V3/E3 and E3/V3 did no show a preference for the novel animal.   
 
Timing and duration of E2 treatment have region-specific effects on gene expression  
Several families of genes were most commonly identified in our model: the 
neuropeptides oxytocin and vasopressin (and receptors); dopamine receptors; other 
neuropeptide, neurotransmitter, and neurotrophic factor signaling systems. Several 
steroid hormone receptor genes were differentially affected by treatment, with different 
genes identified for the 5 regions. We will focus our discussion on the nonapeptide 
(oxytocin, vasopressin) and dopamine receptor results, followed by brief discussion of 
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regional differences in outcomes. 
 
Oxytocin, vasopressin, and their receptors in the MeA, PVN and PFC, were sensitive to 
timing and duration of E2 in aging rats 
 Oxytocin (Oxt), vasopressin (Avp) and their receptors (Oxtr, Avpr1a) are among 
the best-studied neural systems involved in the regulation of social behaviors (see review 
papers Young, 1999; Neumann & Landgraf, 2012). Oxt and Avp are synthesized 
primarily in neurons of the SON and PVN of the hypothalamus; they, and their receptors, 
are also expressed in the MeA, BNST and PFC (Axelson & van Leeuwen, 1990; Bale et 
al., 1995; Smeltzer et al., 2006; Yoshimura et al., 1993; Young, 1999; Štefánik et al., 
2015).  
In the current study we found that E2 had unique timing and duration effects in 
the MeA, PVN and PFC. In the MeA, Oxt was highest in the E3/V3 switch group 
compared to the V3/E3 group or the V6 group. This means that immediate E2 given at 
the time of OVX has unique and long-lasting effects. Avp in the MeA was also highest in 
the E3/V3 group, this time relative to either 6-month treatment (V6 or E6). A different 
pattern and subset of genes were seen in the PVN. Avp expression was unaffected in this 
region, but Oxt expression was highest in the E6 group compared to either V6 or V3/E3, 
indicating that longer duration of estradiol has different effects from shorter-term 
treatment.  
The receptors for oxytocin and vasopressin also had unique expression patterns, 
indicative of specific timing and duration effects. In the PFC, both receptors Oxtr and 
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Avpr1a were highest in the E6 rats. In the PVN Oxtr was higher in the V3/E3 compared 
to V6 rats, indicative of a timing (delayed E2 treatment) effect. These findings are 
interesting because the literature on E2 regulation of these genes is mixed, with some 
studies showing up-regulation (Grassi et al., 2010 [PVN]; de Vries et al., 1986 [MeA]; 
Patisaul et al., 2003 [MeA]), down-regulation (Nomura et al., 2002 [MeA]; Shughrue, 
Dellovade & Merchenthaler, 2002 [PVN]) or no changes (Nomura et al., 2002 [PVN]; 
Patisaul et al., 2003 [PVN]) in response to E2. Also, to our knowledge this is the first 
study to show effects of E2 on Oxtr and Avpr1a expression in the PFC. It is important to 
note that prior studies looked at relatively short-term E2 treatments and did not take into 
account the animals’ age at euthanasia. Our findings add to the literature by showing that 
the age of the animal along with the timing and duration of E2 play important roles in 
determining its effectiveness.  
 
Delayed E2 treatment down-regulated dopamine receptors in the MeA and SON 
 Dopamine receptors play roles in anxiety, depression and social behavior 
(Morgan et al., 2002; Leblois et al., 2010; Skuse & Gallagher, 2009; Morissette & Di 
Paolo, 1993; Bazzett & Becker, 1994; Lammer et al., 1999). These behaviors are sexually 
dimorphic in humans, with depression and anxiety higher in women than in men (Wong 
& Licinio, 2001). Women experiencing menopause have been shown to have increases in 
affective dysfunctions (Freeman et al., 2004; Schmidt et al., 2004; Bromberger et al., 
2011). Dopamine receptors are also well known to be E2-sensitive (Morissette & Di 
Paolo, 1993; Bazzett & Becker, 1994; Lammer et al., 1999). In fact, prior work 
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conducted in other brain regions reported that estrogen treatment led to hyposensitivity 
whereas the loss of estrogen caused hypersensitivity (Roy, Buyer & Licari, 1990; Bédard 
et al., 1983; Gordon & Perry, 1983).  
 In our study, both Drd1 and Drd2 in the MeA were lowest in the V3/E3 rats, 
especially relative to the V6 group. A similar pattern was seen for Drd2 in the SON. Our 
companion study conducted in mature adult rats found a similar result (Garcia et al., 
unpublished). Thus, the timing and duration of E2 treatment are important factors in gene 
regulation in this brain region.  
 
CONCLUSION 
The current study is the first to look at the effects of timing and duration of 
estradiol on social behavior and gene expression in aging female rats. As a whole, our 
findings demonstrate that for social behavior, the “critical window” hypothesis may be 
age dependent, and that molecular actions caused by different modes of E2 treatment are 
region- and gene-specific.  
The relationships between the behavioral outcomes and the neuromolecular gene 
profiles are not straightforward; this is not surprising considering that each gene can play 
multiple roles within a specific brain region due to heterogeneity within any nucleus. 
However, we did have some initial predictions about roles of Oxt, Oxtr, Avp, Avpr1a, 
Drd1 and Drd2 in regulating social behavior based on the literature (Choleris et al., 2006; 
Hlinak, 1993; Egashira et. al, 2007; Ferguson et al., 2001; Murakami et al., 2011; Paul et 
al., 2014; Heinrichs & Domes, 2008; Morgan et al., 2002; Leblois et al., 2010; Skuse & 
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Gallagher, 2009), and expected to find correlations between gene expression and social 
behavior. However, while many genes had altered expression at 6 months, we found no 
timing or duration effects of E2 on social behavior at that 6-month testing period. Future 
work is needed to investigate gene expression in rats after 3-months of testing to relate to 
the time when behavioral changes are seen. 
Nevertheless, several aspects of our study were novel. The USV test designed for 
this study appears to be a robust test for social interactions, and potentially for measuring 
social memory, in rodents. The application to same-sex cagemates adds a new social 
context to previous studies utilizing USV communications as indices of sexual or 
motivational status. Our findings may also have implications for human research 
examining the role of estradiol in a social context, which is currently very limited. 
Translation of this research may be able to demonstrate that the “critical window” 
hypothesis is indeed relevant to anxiety, depression, and a sense of social isolation in 
women experiencing menopause naturally or surgically.  
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  Relative to V6  Relative to E6  Relative to V3EV  
 Gene E6 V3E3 E3V3 V3E3 E3V3 E3V3 
BNST Oxtr --- --- ê  --- --- é 
SON 
Igf1 --- ê  ê  ê  --- --- 
Drd2 --- ê  --- ê  --- --- 
PFC 
Oxtr é --- --- --- --- --- 
Avpr1a é --- é --- --- --- 
Esr2 --- --- ê  --- --- --- 
Bdnf ---	 é	 é	 é	 é	 --- 
 
 
 
PVN 
 
 
 
 
Oxtr ---	 é	 ---	 ---	 ---	 --- 
Oxt é	 --- ---	 ê 	 ---	 ---	
Ar é	 é ---	 ---	 ---	 ---	
Pgr é	 é ---	 ---	 ---	 ê 	
Crh é	 é ---	 ---	 ---	 ê 	
Dnmt3a ---	 --- ---	 ---	 ---	 é	
Egr1 ---	 --- é	 ---	 ---	 ---	
Tac3 ---	 é ---	 ---	 ---	 ---	
MeA 
Oxt ---	 --- é	 ---	 ---	 é	
Avp ---	 --- é	 ---	 é	 ---	
Ar ---	 --- é	 ---	 ---	 ---	
Drd1 ---	 ê ---	 ê 	 ---	 é	
Drd2 ---	 ê ---	 ---	 ---	 ---	
Htr2a ê 	 --- ---	 ---	 é	 ---	
Gabbr1 ---	 --- ---	 ê 	 ---	 ---	
Grin2d ê 	 ê ---	 ---	 é	 ---	
Oprd1 ê 	 --- ---	 ---	 é	 ---	
Dnmt1a ---	 --- ---	 ---	 ---	 é	
Dnmt3a ---	 --- ---	 ---	 é	 é	
Nr3c1 ---	 --- ---	 ---	 é	 é	
 
Table 2.1: Significant changes in gene expression 
 
List of significant changes in gene expression in each of the 5 brain regions. Down-
regulation is indicated by red arrows and up-regulation is indicated by green.  
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SUPPLEMENTAL TABLE 
Gene Name 
Steroid hormone receptors 
Esr1 Estrogen Receptor Alpha 
Esr2 Estrogen Receptor Beta 
Ar Androgen Receptor 
Pgr Progesterone Receptor 
Nr3c1 Nuclear Receptor Subfamily 3, Group C, Member 1 (glucocorticoid receptor 
Oxytocin and vasopressin signaling 
Avp Vasopressin 
Avpr1a Vasopressin Receptor 1a 
Oxt Oxytocin 
Oxtr Oxytocin Receptor  
Neurotransmission 
Drd1a Dopamine Receptor D1A 
Drd2 Dopamine Receptor D2 
Htr1a 5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled 
DBH Dopamine Beta-Hydroxylase (Dopamine Beta-Monooxygenase) 
Slc6a3 Solute Carrier Family 6 (Neurotransmitter Transporter, dopamine), Member 3 
Slc6a4 Solute Carrier Family 6 (Neurotransmitter Transporter, dopamine), Member 4 
Htr2a 5-Hydroxytryptamine (Serotonin) Receptor 2A, G Protein-Coupled 
Htr2C 5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled 
Oprm1 Opioid Receptor, Mu 1 
Oprk1 Opioid Receptor, Kappa 1 
Oprd1 Opioid Receptor, Delta 1 
Grin1 Glutamate Receptor, Ionotropic, N-methyl D-aspartate 1 
Grin2a Glutamate Receptor, Ionotropic, N-methyl D-aspartate 2A 
Grin2b Glutamate Receptor, Ionotropic, N-methyl D-aspartate 2B 
Grin2c Glutamate Receptor, Ionotropic, N-methyl D-aspartate 2C 
Grin2d Glutamate Receptor, Ionotropic, N-methyl D-aspartate 2D 
Gria1  Glutamate Receptor, Ionotropic, AMPA 1 
Gria2 Glutamate Receptor, Ionotropic, AMPA 2 
Gabbr1 GABA B Receptor 1 
Gabbr2 GABA B Receptor 1 
Growth factor signaling 
Bdnf Brain-Derived Neurotrophic Factor 
Igf1r Insulin-Like Growth Factor 1 Receptor 
Igf1 Insulin-Like Growth Factor 1 
Egr1 Early Growth Response 1 
Epigenetic signaling 
HDAC1 Histone Deacetylase 1 
HDAC4 Histone Deacetylase 4 
HDAC2 Histone Deacetylase 2 
DNMT1 DNA (cytosibe-5-)-methyltransferase 1 
DNMT3a DNA (cytosibe-5-)-methyltransferase 3 alpha 
DNMT3b DNA (cytosibe-5-)-methyltransferase 3 alpha 
Other 
Crh Corticotropin Releasing Hormone 
Foxp2 Forkhead Box P2 
Foxp1 Forkhead Box P1 
Nlgn3 Neuroligin 3 
Shank1 SH3 and Multiple Ankyrin Repeat Domains 1 
Tac3 Tachykinin 3 
Table S2.1: List of 45 neuroendocrine genes quantified using Taqman low-density arrays 
(does not include 3 house-keeping genes, Gapdh, Rpl13a, and 18s).  
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CHAPTER 5: GENERAL DISUCSSION 
My overall goal was to examine how the timing and duration of estrogen therapy 
affect the social brain and behavior as a function of aging, estradiol treatment, and their 
interactions. When taken together my 3 experiments provide evidence that estradiol plays 
a role in regulating social behavior and gene expression. In particular all three research 
chapters found that estradiol has specific effects of neuropeptides Oxt and Avp as well as 
their receptors, which are known to be involved in regulating social behavior. Chapter 4 
demonstrates that the “critical window” hypothesis holds up for these specific 
neuropeptides as well as neurotransmitters such as Drd1, Drd2, Htr1a, and Htr2a. 
Overall, these experiments support my hypothesis that estradiol plays a role in regulating 
social behavior and that timing and duration of estradiol affects the underlying 
mechanisms involved in the regulation of social behaviors.  
 
ESTROGEN REGULATION OF SOCIAL BEHAVIOR  
With chapters 3 and 4 I was able to examine the effects of timing and duration of 
estradiol treatment on social communication, memory, and preference. Both the mature 
adult and aging female rats that were treated with 3-months of estradiol spent 
significantly less time interacting with their cagemate than the vehicle animals which is 
another indication of increases social memory. Surprisingly, in the experiment described 
in chapter 4 I found that at the 6-month testing period there was no differences between 
groups on total amount of USVs emitted nor on time spent interacting. One of the 
contributing factors for this lack of treatment effect at the 6-month testing period could be 
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age. Research examining age related changes in rats have demonstrated that aged animals 
have increased anxiety, decreased social interaction and novelty preference compared to 
younger counterparts (Salchner, Lubec & Singewald, 2004; Guan & Dluzen, 1994; 
Boguszewski & Zagrodzka, 2002). It is interesting that the aging animals in chapter 4 
showed a similar pattern to the mature adult rats in chapter 3 after 3-months of treatment 
considering the animals used in chapter 3 were approximately 7-months of age at the time 
of testing and the animals in chapter 4 were approximately 14-months of age at the first 
round of testing. It appears that there may be a critical time between 14- and 17-months 
of age in which there is a loss in sensitivity to the hormone in female rats. The literature 
looking at age related changes on social memory and social interaction are very limited. 
Though a previous study found that there was a significant difference in time spent 
interacting with a novel male rat between male rats that were 15-months old and rats that 
were 22-months old with the older rats spending less time exploring the novel animal 
(Guan & Dluzen, 1994). To my knowledge there are no studies to data that compare 
social memory or social interaction between young and aging female rats. These findings 
indicate that aging in females may affect social behavior in a similar manor as it does in 
males. Further investigation is warranted on this topic and future studies should examine 
social memory and social interaction in the context of aging in female rats.  
I must also note that since our study had two identical testing periods it is 
plausible that the animals were habituated to the test, which had an impact on the results. 
However, I think this to be unlikely because of the large gap in time between testing 
periods and the fact that they were only exposed to the USV chamber for a total of 2 days 
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in the first round of testing. Past research has shown that even after several trials in the 
same testing apparatus rats will still demonstrate increased social interaction if a novel 
animal is introduced (Sánchez-Andrade & Kendrick, 2011; Choleris et al., 2003; Choleris 
et al., 2007; Spiteri & Ågmo, 2009).  
For the sociability test, I saw few effects of estradiol on social interaction and 
novelty preference in the experiments in chapters 3 and 4. Though in chapter 3 I found 
that both vehicle and estradiol treated animals preferred to spend more time with their 
cagemate that they did with the novel animal. This was an unique finding because 
previous literature shows that rats typically spend more time with novel than familiar 
animals (Markham & Juraska, 2007; Carr et al., 1976; Berlyne, 1950; Bevins & Besheer, 
2006), but it is important to note that these studies were conducted using male rats. One 
study using both male and female rats found that female rats exhibit a lower novelty 
preference than males (Cyrenne & Brown, 2011). Also, at the 3-month testing period 
estradiol decreased total time immobile and increased total distance traveled and mean 
speed. By contrast, at the 6-month testing period all groups were around the same for all 
3 of these measures. I attribute this to the age of the animals, as age has been shown to 
decrease locomotor activity in male and female rats (Willig et al., 1987; Jucker et al., 
1988; Altun et al., 2007). A list of significant changes that were found for the USV and 
sociability test in chapters 3 & 4 are provided in Supplemental Table S3.1. 
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TIMGING AND DURATION OF ESTRADIOL ON GENES 
INVOLVED IN SOCIAL AND AFFECTIVE BEHAVIOR 
One of the main goals of this dissertation was to gain a better understanding of 
how estrogen regulates the underlying molecular mechanisms involved in social 
behavior. The neuropeptides oxytocin, vasopressin and their receptors have all been 
shown to be regulated by estradiol. For chapters 2 and 4 there were specific regulatory 
patterns of timing and duration of estradiol, and in Chapter 3 3-months of estradiol 
treatment up-regulated all of these genes in a region specific manor. In chapters 2 and 4 
similar experimental designs were used: both included 6-month treatment groups, which 
received either estradiol or vehicle, and they also included two switch groups that started 
on either estradiol or vehicle then switched treatments after 3 months. In chapter 2, I only 
focused on 5 genes and 2 brain regions whereas in chapter 4 I looked at 42 genes and 5 
brain regions.  
When I compare groups, genes and brain regions that are the same in both 
experiments I did not find complimentary findings. In chapter 2 I did not find any effects 
of timing and duration on Oxt, Avp or their receptors in the PVN, whereas in chapter 4 
delaying estradiol treatment for 3-months increased Oxtr expression compared to the V6 
group. Also, 6-months of estradiol treatment increased Oxt expression compared to both 
V6 and V3/E3 group in the PVN. Additionally when I compared the mature adult groups 
(3-months of vehicle or estradiol) in chapters 2 and 3 I did not find similar results. In 
chapter 2 I did not find any effects of treatment for these groups in the SON. However, in 
 126 
chapter 3 Oxt, Oxtr, and Avp were all up-regulated by estradiol compared to vehicle.  The 
discrepancy in these findings could be attributed to the small number of animals in some 
of the groups in chapter 2. Some of the tissue samples from those animals were damaged 
due to over exposure to RNAlater. Rather than risk using a brain that I could not 
distinguish the regions I opted to use a smaller number of tissues to guarantee that I was 
getting the correct brain regions. However, this could be a major contributing factor to 
the lack of similar results between my experiments. With a small sample size I may have 
missed differences that would have been significant with a larger sample size. Thus the 
rest of this section will focus on the findings from chapter 3 and 4. Table 3.1-3.3 compare 
gene expression results between chapters 2, 3, and 4. In addition, all significant gene 
expression findings for each of the experiments are provided in Supplemental Table S3.2. 
In chapter 3, before performing a false discovery rate (FDR), Oxtr expression was 
up-regulated by estradiol in all 5 brain regions. After FDR Oxtr was significantly up-
regulated in the BNST, MeA, and SON. This supported by previous literature showing 
that Oxtr expression is increased in the BNST and SON in the latter phases of pregnancy 
and partition (Meddle et al., 2007; Young et al., 1997). Also, short-term estradiol 
treatment after OVX increases Oxtr expression in the MeA (Quiñones-Jenab et al., 1997; 
Patisaul et al., 2003). Both Oxt and Avp expression were increased in the SON after 3-
months of estradiol treatment. Previous research has demonstrated that estrogen regulates 
Avp and Oxt in the SON predominantly through the ERβ (Winslow and Insel, 2004; 
Hrabovszky et al, 1998). Yet, our findings are contrary to other studies in rodents that 
have examined the effects of estradiol on Oxt and Avp expression in the SON, most of 
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them have found that estradiol treatment decreases expression if administered after OVX 
(Shughrue et al., 2002; Van Tol et al., 1988) while others found not changes in 
expression (Peter et al., 1990; Rhodes et al., 1981). These studies used either acute 
injections of estradiol or very short-term treatments (>1 month). Longer term treatments 
are more clinically relevant since 3-months in a rats life is thought to be equivalent to 5 
years in humans (Sengupta, 2013; Quinn, 2005), which is comparable to a duration of 
time women would be on hormone replacement therapy. The fact that we see an increase 
in regulation could be an indicator that estradiol must be on board for a relatively long 
period of time before an increase is observed.  
When these results are taken into consideration with the results from the USV test 
it is probable that the increase we see in these neuropeptides from estradiol plays a role in 
the increase in social memory. This conclusion is supported by previous research that has 
found that OVX female rats also show impaired social memory and this deficit is restored 
after estradiol (Hlinak, 1993; Tang et al., 2005) or estrogen plus progesterone treatment 
(Spiteri & Ågmo, 2009). Also, oxytocin and oxytocin receptor knockout mice do not 
habituate to the repeated presentation of a familiar mouse unlike their wild-type 
counterparts (Choleris et al., 2003; Ferguson et al., 2000; Lee et al., 2008; Takayanagi et 
al., 2005; Bielsky et al., 2004). OxtKO and OxtrKO mice cannot distinguish between a 
familiar mouse and a novel mouse, which illustrates a lack of social recognition 
(Takayanagi et al., 2005; Choleris et al., 2006).  
In chapter 4 there were a variety of timing and duration effects of estradiol on the 
neuropeptides involved in social behavior. In the MeA, immediate E2 
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OVX but removed 3-months prior to euthanasia was able to induce increased Oxt and 
Avp expression. In contrast, in the PVN Oxt expression was highest in the E6 group 
compared to either V6 or V3/E3, indicating that longer duration of estradiol has different 
effects from shorter-term treatment. Interestingly we found that Oxtr and Avpr1a 
expression was increased by 6-month estradiol treatment in the PFC. To my knowledge 
this is the first study to show effects of estradiol on these receptors in the PFC. These 
findings are important because previous literature looking at the effects of estradiol on 
these genes is mixed, with some studies showing up-regulation (Grassi et al., 2010 
[PVN]; de Vries et al., 1986 [MeA]; Patisaul et al., 2003 [MeA]), down-regulation 
(Nomura et al., 2002 [MeA]; Shughrue, Dellovade & Merchenthaler, 2002 [PVN]) or no 
changes (Nomura et al., 2002 [PVN]; Patisaul et al., 2003 [PVN]). These varying 
responses to estradiol may be responsible for the lack of differences that were observed in 
the social behavior tests at the 6-month testing period. Understanding the relationships 
between the behavioral outcomes and the neuromolecular gene profiles are not 
straightforward; this is not surprising considering that each gene can play multiple roles 
within a specific brain region due to heterogeneity within any nucleus. However, as 
stated previously, the lack of differences in social behavior between the groups at the 6-
month testing period could have been due to the age of the animals at the time of testing. 
The effect of age appears to have abrogated estradiol’s up-regulation of these 
neuropeptides from inducing behavioral changes.  
Interestingly, in the MeA of the aging animals and the SON of the mature adult 
rats, 3 months of estradiol given immediately following OXV led to a decrease in Drd2 
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expression. In addition, Htr2a was decreased by 6-months of estradiol treatment in the 
MeA of the aging animals and Htr1a was decreased by 3-months in the SON of the 
mature adult rats. These genes have been shown to be involved in regulating affective 
disorders such as anxiety and depression (Dunlop & Nemeroff, 2007; Noble, 2003; Arias 
et al., 2001; Frisch et al., 1999). The current findings are important because it 
demonstrates that estradiol does not just regulate these genes in the mesolimbic system, 
which has been the focus of a majority of studies (Roy et al., 1990; Bédard et al., 1983; 
Gordon & Perry, 1983; Lammers et al., 1999). The fact that both the mature adult and 
aging female rats show a decrease in these genes with estradiol treatment means that 
estradiol could have benefits in the treatment of affective disorders such as depression 
despite age. Previous research has shown that estradiol does play a regulatory role in 
modulating affective disorders (McQueen, Wilson & Fink, 1997; Sumner & Fink, 1993 
& 1995, Biegon & McEwen, 1982; Raap et al., 2000; Charoenphandhu et al., 2011; Mize, 
Poisner & Apler, 2001, Klemenhagen et al., 2006; Parks et al., 1998; Ramboz et al., 
1998, Lerer et al., 1999). 
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Gene Brain region Age (Ch.2) Treatment (Ch.2, 3, & 4) Timing & Duration (Ch. 2 & 4) 
Oxt 
SON  E3 > V3 (Ch.3)  
PVN   E6 > V3 & V3/E3 (Ch.4) 
MeA   E3/V3 > V6 & V3/E3 (Ch.4) 
     
Oxtr 
SON AG > MAT E3 > V3 (Ch.3) V3/E3 > E6 & E3/V3 (Ch.2) 
PVN  E3 > V3 (Ch.2) V3/E3 > V6 (Ch. 4) 
MeA  E3 > V3 (Ch.3)  
BNST  E3 > V3 (Ch.3) V6 & V3/E3 > E3/V3 (Ch. 4) 
PFC  E6 > V6 (Ch.4)  
     
Avp SON  E3 > V3 (Ch.3) V6 > E6 & E3 (Ch.2) PVN   E3/V3 > V6 & E6 (Ch. 4) 
     
Avpr1a 
SON AG > MAT   
PVN AG > MAT   
PFC   E6 > V6 & E3/V3 (Ch. 4) 
Table 3.1: Oxt, Oxtr, Avp, Avpr1a gene expression changes across chapters 2-4 
This table allows for comparison of genes that were studied in parallel in chapters 2, 3, 
and 4. Changes in expression are broken down by age, treatment, as well as timing and 
duration of treatment.  
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Brain Region Gene Mature Adult Rats (Chapter 3) Aging Rats (Chapter 4) 
SON 
Esr1 E3 < V3   
Avp E3 > V3  
Oxt E3 > V3   
Oxtr E3 > V3   
Drd1a E3 < V3   
Drd2  V3/E3 < V6 & E6 
Grin2b E3 < V3   
Gabbr1 E3 < V3   
   
Hdac2 E3 < V3   
Hdac4 E3 < V3   
Foxp2 E3 < V3   
Igf1  V3/E3 > V6 & E6   
  E3/V3 > V6   
PVN 
Oxtr  V3/E3 > V6 
Oxt  E6 > V6 & V3/E3 
Ar  V3/E3 > V6 & E6 
Pgr E3 > V3  E3/V3 > V6 & E3/V3 
 E6 > V6 (Ch.4)  
Crh  E6 & V3/E3 > V6 
  V3/E3 > E3/V3 
Dnmt3a  V3/E3 < E3/V3 
Egr1  E3/V3 > V6 
Tac3   V3/E3 > V6 
MeA 
Oxt  E3/V3 > V6 & V3/E3 
Oxtr E3 > V3   
Avp  E3/V3 > V6 & E6 
Ar  E3/V3 > V6 
Drd1  V3/E3 < V6, E6, & E3/V3 
Drd2  V3/E3 < V6 
Htr2a  E6 < V6 & E3/V3 
Gabbr1  E6 > V3/E3 
Grin2d  E6 & V3/E3 < V6 
  E6 < E3/V3 
Oprd1  E6 < V6 & E3/V3 
Dnmt1a  V3/E3 < E3/V3 
Dnmt3a  E3/V3 > E6 & V3/E3 
Nr3c1  E3/V3 > E6 & V3/E3 
Foxp1 E3 > V3  
Tac3 E3 < V3  
BNST 
Esr2 E3 > V3  
Oxtr E3 > V3 E3/V3 < V6 & V3/E3 
Dnmt3a E3 > V3  
PFC 
Oxtr  E6 > V6 (Ch. 4) 
Avpr1a  E6 > V6 & E3/V3 
Esr2  E3/V3 < V6 
Bdnf  V6 < V3/E3 & E3/V3 
  E6 < V3/E3 & E3/V3 
 
Table 3.2: Gene expression changes in chapters 3 & 4 
This table allows for comparison of genes that were studied in parallel in chapters 2 and 
4. Changes in expression are broken down by treatment as well as timing and duration of 
treatment. Important to note that chapter 3 used mature adult female rats (~7 months) 
while chapter 4 used aging female rats (~17 months).  
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CONCLUSION, CLINICAL IMPLICATIONS, AND FUTURE 
DIRECTIONS 
 
 The results of this dissertation add significant insight into the effects of timing 
and duration of estradiol treatment on gene expression and behaviors involved in social 
behavior. The overall findings from this dissertation suggest that 1) estradiol treatment 
may only be beneficial to social memory for a specific period of time immediately 
following ovariectomy; 2) there are age-related changes in social memory in female rats; 
3) estradiol treatment increases expression of neuropeptides involved in the regulation of 
social behavior in mature adult female rats; 4) there are unique patterns of timing and 
duration of estradiol on neuropeptides involved in the regulation of social behavior in 
aging female rats; 5) the increase in neuropeptide expression in aging female rats is not 
able to compensate for the age-related changes in social behavior; and 6) estradiol 
decreases expression of dopamine and serotonin receptors which may relate to affective 
disorders. These results may have important clinical implications, as menopause is 
associated with an increase in anxiety, depression, and social isolation.  Previous research 
has postulated that estradiol’s regulation of serotonin receptors could impact a woman’s 
responses to serotonin modulating drugs, which are often used to treat anxiety and 
depression (Fischette, Beigon & McEwen, 1983; Kendall, Stancel & Enna, 1981; 
Rubinow, Schmidt & Roca, 1998). Research has focuses mostly on the role of estradiol in 
depression and anxiety but the literature on its role in social behavior is limited and 
warrants further research. The effects of timing and duration of estradiol on gene 
expression suggests that the “critical window” hypothesis is important for some genes but 
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not for others and that its effects are region specific. More studies need to be conducted 
on this topic in order to gain a more comprehensive understanding of timing and duration 
of estradiol on gene expression.  
In addition, the USV test used in this dissertation has proven to be a robust way to 
way to measure social memory in the context of familiar female-to-female social 
interactions. It would be interesting for a future study to examine the differences in USVs 
when female rat is exposed to her cagemate and a novel female rat. In this dissertation 
this setup was used in the sociability test but we did not expose the cagemates to novel 
animals during the USV test. The sociability test did not allow for direct physical 
interaction and no USVs were recorder during the trials. By slightly modifying the setup 
of the USV test to include a novel animal it would help to further validate the use of this 
test for measuring social memory. This dissertation also helped to fill a gap in the USV 
literature examining the types of communications between same-sex cagemates, which to 
my knowledge has not been done previously. Though there were no timing or duration 
effects seen in the USV test, future research should examine these treatments in other 
social and affective behavioral tests. Overall this work represents a unique contribution to 
our understanding of the effects of estradiol treatment following the loss of steroid 
hormones and will consequently benefit the field of women’s health. 
  
 134 
SUPPLEMENTAL TABLES  
 
Behavior MAT AG 
USVs 3 mon. 3 mon. 6 mon. 
Total E2 < Veh (T2 & 3) E2 < Veh (T2 & 3) ----- 
FM ----- E2 < Veh (T2) E6 & V3/E3 < V6 & E3/V3 
NFM E2 < Veh (T3) E2 < Veh (T2 & 3) ----- 
USV Behavior 3 mon. 3 mon. 6 mon. 
Activity E2 < Veh ----- ----- 
Time Interacting  E2 < Veh E2 < Veh ----- 
Anogenital Invest. E2 > Veh ----- E3/V3 < E6, V6 & V3/E3 
Sociability 3 mon. 3 mon. 6 mon. 
Total Time Immobile E2 < Veh E2 < Veh ----- 
Immobile Near Stim. E2 CM > E2 Nov 
Veh Nov > E2 Nov 
----- ----- 
Time Near Stim. E2 & Veh CM > E2 & Veh Nov ----- V6 CM > V6 Nov 
Mean Distance  ----- E2 > Veh ----- 
Mean Speed ----- E2 > Veh ----- 
 
Table S3.1: Significant behavioral changes in the USV and sociability test for chapter 3 
& 4  
Abbreviations: T2 = Trial 2, T3 = Trial 3, CM = Cagemate, Nov = Novel 
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Brain Region Gene Chapter 2 (All groups) Chapter 3 (MAT) Chapter 4 (AG) 
SON 
Esr1 ----- E3 < V3 ----- 
Oxt ----- E3 > V3 ----- 
Oxtr MAT-V3 & E3 < AG-V3 & E3 
AG-V3/E3 > AG-E6 & AG-E3/V3 
E3 > V3 ----- 
Avp AG-E6 < AG-V6 & AG-E3 E3 > V3 ----- 
Avpr1a MAT -V3 & E3 < AG-V3 & E3 ----- ----- 
Drd1a ----- E3 < V3 ----- 
Drd2 ----- ----- V3/E3 & E3/V3 < V6 
Grin2b ----- E3 < V3 ----- 
Gabbr1 ----- E3 < V3 ----- 
Hdac2 ----- E3 < V3 ----- 
Hdac4 ----- E3 < V3 ----- 
Foxp2 ----- E3 < V3 ----- 
PVN 
Oxt ----- ----- E6 > V6 & V3/E3 
Oxtr MAT-V3 < MAT-E3  
AG-V3 < AG-E3 ----- 
V3/E3 > V6 
Avpr1a MAT -V3 & E3 < AG-V3 & E3 ----- ----- 
Pgr ----- E3 > V3 ----- 
Ar ----- ----- V6 < E6 & V3/E3  
 ----- ----- V3/E3 > E3/V3 
Crh ----- ----- V6 < E6 & V3/E3  V3/E3 > E3/V3 
Dnmt3a ----- ----- V3/E3 > E3/V3 
Egr1 ----- ----- E3/V3 > V6 
Tac3 ----- ----- V3/E3 > V6 
MeA 
Oxt ----- ----- E3/V3 > V6 & E3/V3 
Avp ----- ----- E3/V3 > V6 & E6 
Oxtr ----- E3 > V3 ----- 
Drd1 ----- ----- V3/E3 < V6, E6 & E3/V3 
Drd2 ----- ----- V3/E3 < V6 
Htr2a ----- ----- E6 < V6 & E3/V3 
Ar ----- E3 > V3 E3/V3 > V6 
Grin2d ----- ----- V6 > V6 & V3/E3 E6 < E3/V3 
Gabbr1 ----- ----- E6 > V3/E3 
Oprd1 ----- ----- E6 < V6 & E3/V3 
Dnmt1a ----- ----- V3/E3 < E3/V3 
Dnmt3a ----- ----- E3/V3 > E6 & V3/E3 
Nr3c1 ----- ----- E3/V3 > E6 & V3/E3 
Foxp1 ----- E3 > V3 E3/V3 < V6 & V3/E3 
Tac3 ----- E3 < V3 ----- 
BNST 
Esr2 ----- E3 > V3 ----- 
Oxtr ----- E3 > V3 ----- 
Dnmt3a ----- E3 > V3 ----- 
PFC 
Esr2 ----- ----- E3/V3 < V6 
Oxtr ----- ----- E6 > V6 
Avpr1a ----- ----- E6 > V6 & E3/V3 
Bdnf ----- ----- V6 & E6 < V3/E3 & E3/V3 
Table S3.2: Significant changes in gene expression for chapters 2, 3 & 4  
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